{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "aeb1aefd-fd4f-4a60-83bd-3b5c83d25553",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAO0AAAITCAIAAABkKAyYAAAAAXNSR0IArs4c6QAAIABJREFUeJzt3WdcU1cbAPCTRSYr7C1TQFAUVAQ3gjgRxQqO1llHXVXrropSt9a6rdqqdaO4995bQUCGDGWDbLIHvB/im1KFyEhyyc3z//khyV0Pl8fDc0/OPZdQU1ODANBwRKwDAEAJII8BHkAeAzyAPAZ4AHkM8ADyGOABGesAwH98yhFyKiS8SqlYWC3kV2MdzreRKQQSmcDUIzP1SUYWVCoDm5aRAP3HLUFmAjcjnpuRwLFzZYqE1Uw9kqGpjlikAXmsQyVWlUm4lRJuhYRbKWXqkRw8WS7tdRn6JHWGAXmMsfQ4zqMLJZaONCsHur0ni4ZRe6Yseen8jARuSZ6Iba7jP9iISCKo57iQx5gR8auvHy4gkQl+g4z1jSlYh6NksffKH18o7jHMtE0XPTUcDvIYG3np/Iv78odOtza20sE6FhV6dqWUVyXp9Z2pqg8EeYyB0gLR3eiioTOssQ5EHRKfVOak8vr+YK7So0Aeq1tGPDf2bvnQGVZYB6I+755VJb+oHDpdhT+yZl9VaJzKEvHDc5+0KokRQu6ddZ3ase7HfFLdISCP1er2iaLRC+2wjgIDbbvpU2mklJdVKto/5LH6PL1cYuVEJ5LV1BXV0nQIMLwbXaSinUMeq4lYWBN3r7xjEBvrQDBDoRLa9TB4cb1UFTuHPFaTN3fKegxXefdTC+fb3yg3TVAtVf6eIY/VJPFJhY0zQ51HTE9PHzhwYBM2XLBgwYULF1QQEUII0ZjE9HiO0ncLeawORdlChh6Zqd4hB0lJSWresCEcPJiZ8Vyl7xbyWB1yUnmtvXVVtPOCgoKFCxcGBgb6+fmFhYXFxMQghPbs2bNixYqCggIfH5+jR48ihK5evTpq1Khu3boFBAT8/PPPOTk5ss1PnjwZGBh47969wMDALVu2+Pj45OXlRUZG9uzZUxXROrZllReLlb/fGqB6Vw/lp7yqVNHOp0yZMn78+ISEhOzs7Ojo6I4dOz558oTP52/YsKF///5lZWUCgSAhIcHb23vHjh2ZmZkJCQmTJ08ODw+XbR4TE+Pv7z9lypSHDx/m5OQUFhZ6e3sfP368vLxcRQH/tSyDUy5R7j5h/LE6cCukTD1Vneq0tLQRI0a0adMGIRQWFubq6mphYUGj0ahUKoFAMDAwQAjZ2dn9888/zs7OZDIZITRy5Mg5c+aUlpay2WwCgSAQCEaOHOnv748QEgqFCCEGg6Gvr6+igJn6ZG6lRLlVFuSxOvAqJUx9VZ3q7t27HzhwoKqqyt/fv3379h4eHl+vw2KxcnNzt2/fnp2dLRAIxGIxQqiyspLN/twP6OnpqaLwvsbQI3MrJQhRlbhPyGN1IOsQSURVff2xaNEiJyeny5cvHzlyhMlkhoWFTZ06Vdbuyl2/fn3x4sUTJkz45ZdfWCxWbGzswoULa6/AYrFUFN7XdGjEGmXfIQB5rA4UHQKnUqJrpJKzTSaTIyIiIiIiSkpKLl26tHPnTkNDw9GjR9de58yZMz4+PlOnTpW9FQgEqoikgSqKxQxdJXfdQH+FOvz/L6nycTicK1euSCQShJCRkdH333/v6emZlpb2xWoikUhWKMtcvXpVdolf325VOgqSVylR+tUC5LE6mFhRRaq5aZRAIKxbty4qKiolJSU3N/fq1atJSUne3t4IIV1d3eLi4jdv3uTn53t4eDx9+jQhISE/P3/NmjXGxsYIoXfv3n3dMFOpVCqV+vr165SUFNl/D6XTY1NYhkrOY6gr1MHCnvb8aqm7r/Lv8GEymdu3b9++ffvkyZNFIpGlpeWUKVMGDRqEEAoODr548eLUqVPHjh07fvz4nJycqVOnMpnMoUOHTpw48dOnT1FRUSRSHX/fx44de/DgwQcPHpw9e1ZXV8nd3h8SuRQqgaDsiwUYR68mexakj1/pQKFq6WA3udsniszsaG2U/V8a6go1adNFPzuVh3UU2ONWSBw8mErfLdQVauLZVf/8njwHz3p/hatXr75+/Xqdi6RSaZ0FAEIoMjKyR48eygvzPxR8Na0gpOPHj5ub1303XvzDCj0jCp2l/HEmUFeoj+I/qeXl5Txe3Q22UCikUuv+1oDNZtNoNKWG+a+8vLz6FikIydTU9Ivea7ndC9InrHKg6Ci/uII8Vh8Bt/rG4YJBky2xDgQbbx9USCU17XsZNGDdRoP6WH1oTGK7ngbndtfbyOHYxyTexySuipIY8ljdbFszbFszbh1T1W1qLVNlsfj2icJBP6rwDxHUFRhIf8v9+I7bO1wrbnPKzxTcPlE0cr4tQZVtJrTHGHBsyzSxpp7emiOV4LwRSXlZ9eh88aiFqk1iaI+xlJ8puBv9ybEts1MwDm+izk7lP75QbOPC8BtkpIbDQR5jqaYGvbhW+upWWce+bFsXhqmtMofkYkLAq86M5+RnCirLxP6DjE2s1fQTQR5jTyquibtfkRZXxamQuHbUQzWIoUfSY1OqqzXgV0MiE3mVEl6VhFcprSyVFHzkO3iwWnvrWbuoqle7TpDHLQi3UpqXxq8sE/MqpQjVcCqUPNFDYmKinZ2dcofM05mkmuoahh6ZoUsytqJZ2GPzJwXyWIuMGzduzpw56ryFSW2gvwLgAeQxwAPIYy1ibW1NJOLzN47PnwrUKScnp7paA55l1gSQx1qEyVT+APYWAvJYi3C5yp8gsIWAPNYislmwsI5CJSCPtUhpaSlevy6APNYitra20F8BNF5WVhb0VwDQckEeaxEWiwXXeUDjcTgcuM4DGk9PTw/aY6DxKisroT0GoOWCPNYi5ubm0H8MNF5BQQH0HwPQckEeaxEYRw/wAMbRA9CiQR5rERjvBvAAxrsB0KJBHmsR6K8AeAD9FQC0aJDHWgTmrwB4APNXADywsLCA6zyg8fLz8+E6D4CWC/JYixgYGMD9eUDjlZeXw/15QOPZ2NjAdR7QeNnZ2XCdBzQetMcAD6A9BnhgYmKC1/4KeA4k/vXt25dCoRCJxLKyMiaTSSaTiUQihUI5ffo01qEpDRnrAIDKMZnMrKws2Ws+ny97MW3aNEyDUjKoK/AvKCjoi09sbW0jIiIwCkclII/xb/jw4ba2tvK3JBJp8ODBdDod06CUDPIY/4yMjPr06SN/a2dnN3z4cEwjUj7IY60QERFhZ2cna4wHDBiAvwH1kMdawdDQMDAwkEAg2NrahoWFYR2O8kF/hQoJeNXFOUIBX4p1IAgh1KnN4Gf2H7t27ZqfVoMQB+twEIlEMDDRMTSjKGVv0H+sGjXo6j+F2clcKxemVAJnuA4sfVJOKo+pT27f08Deo7l1DuSx8olFNae35nj1MrJyYmAdS0tXI0U3juT6BLDt3JvVfwL1sfKd3prjO9AUkrghCCQU9L3V82sluWn85uwH8ljJUl9VmbViGFlQsQ5Ek/gNNnt9u7w5e4A8VrLCbCGDRcI6Cg2jZ0z5mNSsOQkgj5VMyKvWM9bBOgrNY96KXlksbvLmkMdKJhJIq6X4HOOrUpwKMSI2fUwp5DHAA8hjgAeQxwAPII8BHkAeAzyAPAZ4AHkM8ADyGOAB5DHAA8hjgAeQxwAPII/Bf2RkpPUK8ImPj8U6kMaBPAb/YWxiOnvWQktLa6wDaRy4zxT8h56uXshgzbuhGtpj7F26fHbchO+C+/uHhAYsW/5LUVEhQig55V2vAJ/klHfy1UaPGbJr9xaEUOr75F4BPg8f3v15zuSBg3uEhAbs2r1FPiFs6vvk+Qumh4QGDBjU/ddl8woK8mWfnzl7MnRY4KNH90KHBW7dtr5vP7+jxw7Idy4WiweF9Ny7b3vtukIikezavWVExICg4C7fhfffsXOzWPx5iHB8fOzM2ROD+/v3G9B1ztwpScmJss9XRC6IXLnw7wO7+w3oGhf3Wm3nEPIYY2/fvtm4KWrY0Ij9+06sWf1HRWV55KqFijchk8gIoT17t06aNOP82TsLfll+OubYlavnEUKFhQVz5k4mEIm/b9qzaePuyqqKub9MFYlECCEKhSIQ8GPOHF8wf0VY2KjOnfwfPLwj3+erV884HE5A7+DaBzp67MD1G5fmzf3177+i58xefOfu9QMH9yCEsrM/zps/zcTYdMe2A9u3/k1nMOb9MlX2349CoWRkpqW+T167equDo7PKTtuXII8xlvkhnUqlBvcdZGVp7e7msfzXtT9Nm9uQDQP79Hd38yASiX5+3dt7+Vy7fhEhdP7CKQKBsHTJbw4OTq6t3RcvXJWfn3vv/i2EEIFAEAgEYcNG+nb2t7Sw6tUrKDk58dOnItne7t2/ZW/v6ODg9J/YMtMc7J06+vhaWVr7+nbdvHF3cN9BCKFz50/R6YxFC1c6Ojo7OjovWRQlkUhkAdQglJeXs3BBZLt2HXRZuqo5Z3WAPMZYey8fAoEwc/bEi5fO5BfksdlG7m4eDdnQxdlV/trOziEvLwchlJSU4Nq6jTyBzMzMLSys0tJS5Gu6u3vKXnTx7Uaj0R4+uiurHx4/uf9FY4wQ8uvS/fWbFytXLbp772ZlVaWtbSsbGzuEUOr7JBdnVzL588UVg8GwsbFLT0+VvbWxsdPX02/eWWk0uM7DmK1tq+1b/z524uCfe7dVbf7Nzc1j+k/zGpLKdDqj1ms6h1OFEOJyOe/TUoKCu8gXicXiktJi+VsmkyV7QaPRuvh2e/DgduiQ797EvqysrOjdu+8XhwgM7M9gMM+dj16zdplUKvX36zF71kJDQzaPxzViG9dek8Fg8njcLw6hTpDH2HN0dF66OEoqlcbHx+7/e+fiJbNPHr/89QMQBEJB7bd8Pk/+msvjsli6shzy9PSa+/OS2mvWzvjaevUKily5sKKy4sGD2+7unhbmll+v4+/fw9+/B5/Pf/rs4Y6dmzZsWrU66ncmk8Xl/mdmLS6X80VmqxnUFRhLSkpITHwrmwnTy8t7/LipFRXlpaUlTAYTISRrZRFCZWWlJSXFtTeMjXslf52S8s7WphVCyM3NIzc329LS2ta2lewfgUAwMqo7wzp19KNSqc+fP370+N7XRQVC6OHDu/kFebL2vlfPwAH9h2RmpCGEWru4p6QmyfsuqjhVWVkfXF3bKPXENA7kMcaePX+85Nc59+7fys3LeZ+WEhNz3NzMwszM3NTUXF/f4PqNSxKJpIpTtXXber3/Fp2Pn9y/dftaXn5u9Kkj797F9wsejBAaNHAYn89bt37F+7SUnJysQ//sGzfhu+T/d4p9gUql+vn1OHHyUHl5Wa+egV+vcDrm2MpVi+LiXufl576JfXn33s12Xt4IoZCQ4UKhYP3GldnZHzMy0qJ+W8JksvoGDVTZSfo2qCswNnrUeIlEvHv3luKST0wmy8Oj3do1WwkEgo6OzsIFkTt2bhoU0tPU1HzihJ+KPhXWfmrY+HFTr12/uHHTKh0d6vhxUwMD+yOEzM0tNm/a8+efW2fOmkAikVq1coxatVl+bfe13j2DFt+80tHH19CQ/fXSZb+u2blr8/LI+Vwux8jI2Ldz14kTpiOErCytN6zb8ee+bRN/jCCRSJ4eXr9v2mNgYKiyk/RtME+hkl3+K9+uja6tqwqvdTIy0iZMCt+6ZZ+np5fqjqJmp//4MHS6tR67iQ0r1BUADyCPAR5Afax5HByc7tx6iXUULQu0xwAPII8BHkAeAzyAPAZ4AHkM8ADyGOAB5DHAA8hjgAeQxwAPII8BHkAeKxnTEL7qbwoDEx0SCZ7X1GKwdMmfsoVYR6FhBFxpca6Qqd/052dCHiuZnTuzqkyEdRQapvCDoLVPsyYJgDxWMmNLHSsn+sMzRVgHojFK84WvbhZ3G9Ks21ThfhCViH9UmRHPtXFlGlvSyJSml304RiASygqF3ApJ8rPyUYtsic0ojiGPVSgvXZD0vJJbJSkvbOhjkysqyvX1DVQclwqVlZXV1FSTyWQymUwhU0hkEpFYb8nLttBBNcjKid6+lxJ+ZMjjFiEtLW3cuHEbNmzw9fXFOpamO3To0O7du4VCoew+WV1dXT09PRsbm82bN6v60JDH2IuJiTl58uRff/3FYNQ9YYqm4HK533///cePH+Wf1NTUyBLs9WvVzr0J13kYW7FiRVJS0vHjxzU9iRFCTCYzMDBQPu+bbHJEOp2u6iSGPMZSVVXVvHnzvL29lyxZ0oDVNUNYWJi5uXntTx49eqSG40IeY+PFixeDBg2aOXPmoEGDsI5FmYyNjQMCAuST05mYmKjnuJDHGNi3b9/Nmzfv3r1ra2uLdSzK991331laWiKEzM3Nr1y5ghBavHixQCBowKZNB3msbj///LNEIlm0aBHWgaiKmZmZn58flUq9ePGi7JMZM2acPn1apQeF/gr1KS8vnzt37g8//NC9e3esY8HGwYMHf/jhB1XsGdpjNXn58uWwYcPWrVuntUmMEBIIBIcOHVLFnqE9VofTp0/fuHFj9+7dWAeCvRcvXnTs2FHpu4X2WOU2bdqUlZUFSSwjS+KJEycqd7eQx6o1e/ZsCwuLn3/+GetAWpa1a9euX79eiTuEukKFJkyYMHbs2G7dumEdSEsklUpJpKYPnP8CtMeqEhwcvHDhQkji+pBIpOrq6oCAAKXsDfJY+QQCQefOnQ8fPuzsrL4HemoiIpF49erVHTt2NH9XUFcoGZ/PHzp06IULF2oPlwGKNb/GgPZYmbhcbmBg4JUrVyCJG+Xp06czZ85szh6gPVaa6urq4ODg69evYx2IRoqNjeXxeH5+fk3bHPJYaXx8fF6+hMcdYAPqCuUICgq6du0a1lFovJEjR/L5/CZsCHmsBLNmzdq5c6eRkRHWgWi85cuXr1mzpgkbQl3RXCtWrPD29sbZcHiNA+1xs5w5c4ZMJkMSK9fevXuFwsbNLQZ53HQZGRmPHz9eunQp1oHgja2tbWRkZKM2gbqi6cLDw6OiopycnLAOBIdyc3ONjIxoNFoD14f2uIkOHz7cuXNnSGIVsbCwaNT6kMdNUVFR8eLFCxiNqTpEInH69OmxsbENXV/F8eDTvn37OnfujHUUOPfTTz/dvHmzgStDfdxofD4/MDDw4cOHWAcC/gXtcaOdOnVq6tSpWEehFT58+JCWltaQNSGPG+3UqVM9evTAOgqtwGAwZsyY0ZA1IY8bJy4urlWrVtbW1lgHohVMTU2nTZuWn5//zTVhmGzj3L9/v3379lhHoUUa+F0ptMeN8/z5806dOmEdhRYpKytryI1PkMeNwOfzGQyGu7s71oFoEUNDw2vXruXm5ipeDfK4EdLT0xs7fgU039q1a7/ZOwz1cSNkZ2dDUaF+DfkDCO1xI2RnZytx6hDQQMXFxb///rvidSCPG0EqldrY2GAdhdYxNjaOiYnh8XgK1oE8boS8vDysQ9BSf/zxh+IrE6iPG0FfX19Xt1mPQQZN06FDB8UrwDihbwsMDCQQCAQCgcPh0Gg0EolEIBD09PSio6OxDk1b3L17Nz8/PyIior4VoK74NhaLVVpaWlJSIhQKKyoqSktLi4uL27Zti3VcWoRGoykeYAh5/G2BgYFffGJnZzdixAiMwtFG3t7eiu9agDz+tvDwcDs7O/nbmpqatm3buri4YBqUdqFQKIpvIYM8/jY2m92nTx/5sw3Nzc2hMVa/WbNmffr0qb6lkMcNEh4eLus5rqmpad++vZubG9YRaZ3KykoFAzghjxvE0NBQNnO6ubn5mDFjsA5HG0VGRtau7r7QoP5jsaiGVylRalSap39g2L2bLzw8PMyNHCqKxViHgzF9Y4qaj6j4Gcbf6D9OelYZd7+i/JOIzoJvTMBnbHNqdirXqR2rywAjXbaaEuPSpUs1NTUDBw6sc6miIF5cK/uUL+oeZq7LVvd/PtDCSSU15UWi6C05oT9ZG5qpI5V5PF56enp9eVxve/zsSmlludS3v4mKwwOa7dTmD8NmWeupvlWuqKiorKysb5xW3dd5ZUXi4jwRJDH4pl7hFk8vlajhQPr6+goGG9adx8V5Qhh2ARrCwEQn/S1HDQdKTk5euHBhfUvrzuOqMomJdUOnOgTajEQhWLswKktV3oFDJpMzMzPrXVrnpxJhtUigyqAAjpTkCxEiqPoo9vb2Cm6chu9BgGYgkUjGxsb1LYU8BpqBz+fX1+kGeQw0BoVCgXFCQOORyeRbt27VtxTyGGgMFotV3yLIY6AxBgwYUN/d/5DHQGPweDyJpO5xl5DHQGOcPXu2vnkXYDQm0Bj6+vr1LYL2GGiM0aNHFxcX17kI8hhojNLSUqlUWucipeXx0mVzJ/745XQv8fGxvQJ83sS+VNZR6pSTm90rwOflq2dK2VvMmRMBgY2eHLawsGDLH2tHjQ4JCu4SEhow9acfzpw9Wd9JB03z999/1/fVtKa2x5mZ6eEj6/2Wsjnae/nMnlXv+MA6vXsXP3FS+LNnjwYPDlu5YsOM6b/Y2dpv275heeT8ljDt2JmzJ9euX4F1FEpgZmZW37y9mnqdl5qapKI929s72ts7Nnx9iUSyMmqRmbnFls175R31fQKC23v5bNwcFRv3qr2Xj4pCbSDVnSs1mzFjxrJly0xM6ri9Q015/Or183m/TNv2x34Pj3ayT9LSUidNHrlu7baPHzP+Obz/16Wrd+zcVFiYb6BvOPaHyX37fm5r4+Nj9+7fnpqaRCAQ3Fw9Jk2a4eba5sDBPQcP7UUI9Qrw+WnaHF/fbgghAZ//2+qljx7fIxKJwX0HT50yW/Z/t7y8bOfu3+PiXlVUlDs4OE+aOF2WWBKJZO++7Xfv3SgrKzUwMOzRvc+Pk2ZQKJSYMyd27Nx068ZzWbWwe8+W2LhXPB7X3NwybNjIQQOHfvGjPXp8r7Cw4Jd5y774tqlv34HduvVmMBiytxKJ5PCR/bfvXC8szDcxMRseNipkcJhsUeiwwDGjJhQWFdy+c43P53l6tp83Z6mRkbGC4DMz08dPHPHbqs1/7ttGp9F37TxUVla6a8+W16+fV1VVmpiYDR0yYujQcITQ7Dk/xsW9Rghdu3bxzz1HnJ1a13lKEUIrIhcQCARb21Ynow8vW7qmS5duKk+LRvrw4YNYXPdAZ2XWFdXV1VWcqtr/ePzP3750aN/R0sLqxs3L8pXvP7hlbGzi492ZRCJzuZzo6MObNuw6d+Z2UNCAdRsis7I+IISysz/Omz/NxNh0x7YD27f+TWcw5v0ytaioMHzED0OHhpuamp2NuTlo4DDZDg8e+tPNzXPrlv2jR004HXPs3v1bspAWLJyRmPh2wfwVe3Yddm3tvnDRzIyMNITQ0WMHrt+4NG/ur3//FT1n9uI7d68fOLjni59o/YbI4pJPq3/b8tf+k0NDw7f8sfbFy6dfrBMfH0skEtu1rWNiU3kSI4R27/njxMl/RkWM27/vxPCwUdt3bLx0+axsEZlMPnbiYKtWDseOXPhr38n375P/ObxPcfAUCkX2I4/4bswv85YhhNZvXPku8e2vS1bv+/PYyIixO3ZtfvjoLkIoauVmF2fX3r2CzsbcdLB3qu+UyvaZkZmW+j557eqt7u6eSkoKZdq4cWN99bEy2+PMzPTBIb3qXEQgEIKDB0dHH57+0zzZ7+De/VtBgQOIRKLsFzZm9ERZCzR61IToU0du3b46buyUc+dP0emMRQtXkslkhNCSRVGhw/pcu35xzOgJVB0qgUDQ1zeQH8LHx3do6AiEkJOTS8yZ40lJCb17Bb189Sz1ffLmTbtlzdj0n+a9fPUs5szxeXOXZmamOdg7dfTxRQhZWVpv3rhbPvOVXEZmWuiQEbLmympwmIuzq5mZxRfrlJYWm5iYyiKUEQgE1dXVstdEIpFGo3E4nHPno0eNHCf7O2NtZfP+ffLRYwcG9B8iW83O1r5f8GCEkKmpWaeOfikp7xBCCoJHBAJCyMvLR7YVQuinaXOJRKKlhRVCyMbG7ty56Jcvn3b178lisUhkMkVHR3auFJzSGoTy8nK2/rFfX6/eblpstW7dur5FysxjK0vruXOX1v4kIyNt+46Nstf9ggcfOLjn6bOH3br2ysxMz8r6ELzy30f8OTu7yl5QKBQrS5vc3GyEUOr7JBdnV3mKMBgMGxu79PTUOo/exv3fiVwNDdh8Pg8hlJSUQKFQvNp5yz4nEoltPdunpaUghPy6dF+9dtnKVYu6dw/o0KGTrW2rr/fp16X7seMHOJyqzp3923q2d3Pz+HodIpH4xZelI0cPLisrlb1u167Dls1/pqenSiQSH29f+Trt2nlfunyWx+PJ2mwHB2f5Il1dvcqqSsXBy9RuNek0+tHjB2JjX1ZUlFdXV1dVVVpZ1XFXpuJTamNj12KTGCG0YsWKGTNmGBkZfb1ImXlMo9O/uKYhk/7dv7GxSadOftevX+rWtde9+7fatGlrY/PvNEc0Gq32fqo4VQghHo9rxP7P3xEGg8njces7eu23so4CHo8rFov79vOTfy6VStlsI4RQYGB/BoN57nz0mrXLpFKpv1+P2bMWGhqya+/k59mLHOydbty8HH3qCJPJHDwobPy4qbWbXoSQiYlZSUmxQCCQ/whRqzZLJRKE0OGjfwmFAlkYCKGf506WN/my8ErLSmR5TKVSa+9TtpKC4GWYzM8VuUQimb9wulQqnf7TPFubViQSaemyuXWeJcWnVL7DlunVq1f1PV1Brf0VA/oNWRm1iMvl3n9wa2hoeO1FfD6f/v9E5PG45mYWstPK5f7nXlwul/PFr0ExJpOlo6Ozd8/R2h/KihmEkL9/D3//Hnw+/+mzhzt2btqwadXqqP88F4hMJg8bFjFsWERpacn1G5f2/7XTwMDwu+Gja6/j5eVz/MSh23eu9e8XIvvE/f/NtqEhu6AgT54fSxZHOdj/Z/JTUxOzJgdfW1JSQkZG2h+/723b9vMzgyvKyyzMLevcZzNPKYZWrVpVZ2Os7v5jX9+uenr6x44fyMvL6dnjP5Njx8W9kr3g8XhZWR9sbFohhFq7uKcm/CSWAAAgAElEQVSkJskvUas4VVlZH1xd2zT8iK6ubUQikVQqtbVtJfuno0M1NjZFCD18eDe/IA8hRKfTe/UMHNB/SGZGWu1tORzOjZtXZDUDm20UPuJ7d3fPjP+ugxDq6ONrb+946J+9JSX/+cqUz+d//Pj5/l4HB2cKhVJWVioPQ09PX1/fQEdHp2nBf0EoEiKE9P5fEiQmvs0vyKvddS1/3fxTiiEvL68v/nDJqTWPyWRy36CBx08c6tq1V+1eKhKJdPT4gfj42Ozsj1u2rkUIBQQEI4RCQoYLhYL1G1dmZ3/MyEiL+m0Jk8nqGzQQIcRi6ZaUFL99+6agQNHD4L07dHJ2ar16za+xsa/yC/Ju3rr64+SR585HI4ROxxxbuWpRXNzrvPzcN7Ev79672c7Lu/a2BAJh67Z1GzdFvU9LycvPvXnrampqktd/15E1kL8uWS0WiydMCj/0z74nTx7cf3B7/187x/wQmpubPWb0RNkA8IEDhx44uOf2neuyw82bP+2b300oCP4LTo4uOjo6MWeOl5QUv3j5dOu29R19fLNzPsrKdF2Wblpayvu0lIqKcgWntOVbtmxZSUndc76o+3uQrl17HT12QP4nWO7HiTO2bd+QkZlmYmy6KnKjlaW17MJxw7odf+7bNvHHCBKJ5Onh9fumPQYGhgihgN7B165fnPvL1JERYwMDB9R3OBKJtG7ttl17tiyPnC8Q8M3NLceMmTg8bBRCaNmva3bu2rw8cj6XyzEyMvbt3HXihOm1t2UymevWbt+3b/ucuZNFIpG5ueW4sVOC+9bx+Hl7e8f9e48fO37wxs3LR47+RaFQzM0tBw4IDQ0Nl182TZvysy5L98+9W0tKitlsI78u3SeM/0nxuVIQ/BcMDAzn/7J8377t129ccnFxWzB/xafiolVRi+bMm/L3/pOhoeFr1i6bOWtC5IoNnTp2qe+Utnxv3ryprz6ue36351dLhQLk1Ytd1ybNsufPrU+fPfx7/0n5J7W/dwCa6PQfH4ZOV8cUb7GxsW5ubnWWFuprj7OyPrx89exk9OFVkRvVdlCAJ15eXvUtUl99PGXamGPHD0ybOsfPr7vaDgrwpEXUx5cvPqjz86GhI2TfwwGgmIL6WFPHbQItpKD/WFPHbQIt1CLqYwCaSUF9DHkMNAbUxwAPoD4GeAD1McADqI8BHkB9DPAA6mOAB42uj3XoRB06NNWgQYwsqCp/WhNCTamPdQ0pRR/5Ko4K4IFYWJ2XxlPP09IbXR+b2VC/ugcegDqUF4mcvOqek1jpGn1/HsuQbO1Mv3+qUMWBAY1343Be1yFquk21KffnefU0cPBg3DqSV5wrlIiwn2wPtCjcCkleOv9wVPr3S+2o6rqUauL4Y7fOugxdUuy9kvxMPpQZsnmPCATC19MOaRsTG1pFsdjBgzlptQOZor6z0ej7874mFkKTjJYsWdK3b9/u3eF+lhoKFYPuLCXcn0dRU9dKi1aNRERyNZwKNTwVvU4wvgLgAYyvUA42my2bLBRgAsZXKEdpaWl980gDNYDxFcphbm6ueEY2oFJQHytHQUGBSCTCOgrtBfWxcpiZmUF7jCGoj5WjsLAQ2mMMQX2sHDQarc5ptIF6QH2sHLUfYAPUD+pjgAdQHysHXOdhC+pj5YDrPGxBfQzwAOpj5WCz2V88PA+oE9THylFaWvrFo0uBOkF9DPAA6mPloFKp8D0IhqA+Vg6hUAjfg2AI6mPlgJtMsQX1sXLU1NQ08LZcoApQHwM8gPpYOZhMJlznYQjqY+XgcrlwnYchqI8BHkB9rBxw3z+2oD5WDrjvH1tQHwM8gPpYOWD+CmxBfawcMH8FtqA+BngA9bFywHg3bEF9rBww3g1bUB8rB1znYQvqY+WA6zxsQX2sHAYGBnCfKYagPlaO8vJyuM8UQ1AfK4eenh6JRMI6Cu0F9bFyVFZWSqVSrKPQXlAfK4epqSmMd8MQ1MfKUVRUBOPdMKSgPm7o80y12ZAhQ3JycuQnikAgSKVSX1/fXbt2YR2adlm2bNmsWbPqbJKhrvi2Tp061dTUEP5PNoHspEmTsI5L60B93CwRERE2Nja1P3Fzc+vQoQN2EWkpBfUx5PG32dvb+/r6yusKIyOjiIgIrIPSRl5eXnU+JB3yuKEiIiKsra1lr93c3Dp16oR1RNoI+o+by87OTtYks9nsUaNGYR2OloL6WAm+++47c3NzNze3jh07Yh2LllJQH2tYv9ub2+UZiVwSCRV+FKj/6FKplEAgEokYTFXINKCwzXXa9zSwsKep/+gtnybl8emtOTatdQ3NdYwsaNo27aWAJy0rFCY8LPPuY+jYlol1ONhQ0H+sMd/nRf+R49LewKEdC+tAsMHSIbMMyDatmbeP5fOrJB7++lhHhAEF9bFmtMdvH1TwODVt/AywDqRFuHM8v/d3JixDjWmDlCU2NtbNza3OrjfNuM7LTOQamMINRZ+RKYS8TD7WUWBA4/uPCQgZWcD1zWemtoyqUm0czq+g/1gz/jYV5QgQQQPqH/WQiKVSsTbetg39xwAPYPwxwAO4Pw/gAYyvAHgA9THAA6iPAR5AfQzwAOpjgAdQHwM8gPoY4AHUxwAPoD4GeAD1caNlZKT1CvCJj4/FOhDwL6iPG83YxHT2rIWWltZYBwL+BfVxo+np6oUMDjMyMsY6EPAvrauPz5w9GTos8NGje6HDAnft3oIQkkgkBw7u+X7ssL79/EZ/H3ru/CmEEJfL7dvP7+ixA/INxWLxoJCee/dt/6KuuHX72pSpY/oN6Do0LGj7jk0CgQAhtCpq8Zy5U+Tbfj92WOiwQPnblasWLVw8CyFUXl62eu2yEREDgvv7T5s+9k3sS9kKmZnpvQJ8Hj++P3b88OMnDqnx9GgqrauPKRSKQMCPOXN8wfwVISHDEUK79/xx4uQ/oyLG7d93YnjYqO07Nl66fJbJZHbu5P/g4R35hq9ePeNwOAG9g2vv7eHDu1G/LfH27rz3z2Pzf1l+/8GtTb//hhDq0KFTUnKC7EkLpaUlRUUFNTU12dkfZVu9jX/j4925urp6wcIZiYlvF8xfsWfXYdfW7gsXzczISJMFiRA6eOjPEd+N6RPQT+0nSfNo3fxuBAJBIBCEDRvp29nf0sKKw+GcOx894rsxffsOtLayCRkc1jdooKwZ7tUrKDk58dOnItmG9+7fsrd3dHBwqr23o8cPtGvXYdLE6dZWNr6d/SdNnHHz5pWiokLvDp0FAkFaeipCKDbulaOjS+vW7m/j3yCEcnKzS0qKvTt0fvnqWer75Hlzl3Zo39HOzn76T/PMzCxizhyXRYkQ8vLy6Rc82NjYBJszpVE0/v68pnF395S9SE9PlUgkPt6+8kXt2nnn5eXweLwuvt1oNNrDR3dltcfjJ/e/aIyrq6tTU5Nqb+vVzhshlJHx3tzcwsrSOjEhDiH09u1rTw+vNu5t4xNiZW+NjIzt7R2TkhIoFIpsE4QQkUhs69k+LS3l6yDBN2n8/XlNw2R+nuyCx+MihH6eO5nw/+lbZLMdlJaVWFvZdPHt9uDB7dAh372JfVlZWdG7d9/aOxEIBFKp9MDBPYf+2Vv785LSYllpEZ8QO2xYRGzcq8mTZlJptGvXLsiKCm/vzrJDi8Xivv385BtKpVI2+98/jvIgwTcpqI/xnMdyslxZsjjKwf4/BYOpiZmstIhcubCisuLBg9vu7p4W5pa116HRaGQyeWho+ID+Q2p/bmDIluXx9h0by8vLsrI+tPFop0PRKfpUWFz86W3c63Fjp8gOraOjs3fP0drbwkOqm2bJkiVsNrvORVqRxw4OzhQKpays1LZHK9kn5eVlBAJB9pDdTh39qFTq8+ePHz2+N2rk+C+2JRKJzs6uhYX5traftxWLxUWfCvV09RBC7b18SkqKr167YG/vKPvEydHl9p1r+QV5HTp0Qgi5urYRiURSqdTe3lG2eUFBvoGBoXpPAE74+vrWt0grGgYWizVw4NADB/fcvnM9Lz/3TezLefOnrV2/QraUSqX6+fU4cfJQeXlZr56BX28ePuL7+w9uHz12IDv74/u0lNVrfp05awKXy0UI6esbODu1PnP2RFvP9rKVPTy8Ys4cd3BwkvU9e3fo5OzUevWaX2NjX+UX5N28dfXHySPPnY9W68+PF5s3by4vL69zkVa0xwihaVN+1mXp/rl3a0lJMZtt5Nel+4TxP8mX9u4ZtPjmlY4+voaGdfzZ6t6t9+JFq44dP/D3gd1MJsvDo93vm/YwmZ8nC+zQodOJk/+0bfv5MQuenl6nTh8NGzZS9pZEIq1bu23Xni3LI+cLBHxzc8sxYyYOD4MZlJvizp074eHhBgZ1TI+mGfO77VuaEfKTHY0BzxJFCKHEx2VScbX/4Lp7UnHs+vXrXbt2ZTAYXy/SlvYY4EBQUFB9i7SiPgb4sGvXLg6HU+ciyGOgMc6cOaNd4ysALk2ePJnFqvtrI6iPgcYYNmxYfYugPQYaY8eOHfU9px7yGGiMf/75h1DPA44gj4HGmD59OplcdyUMeQw0xujRo+tbBHkMNINQKNy9e3d9SyGPgWYoLy8/f/58fUshj4FmoNPp06ZNq2+pZvQfG5pR67tQ1UJkHRJR+55epaenN3DgwPqWakZ7XCOtqSgWYR1FS1FaIGDoad3Qvw8fPhw+fLi+pZqRx9bOdE5Z3R3gWqhaUmNsWfdtwziWkZERFxdX31LNqCt8BxjtnJfWqg2LSNL26iLxcTmFSjBvpXVPd23durWZmVl9SzVjHD1CiM+pPrruY+8IS2MrrWuKZCSimviHZWKhJCDcFOtYWhyNyWOEkJBXfS/mU1pslWNb3YoSDMqM6upqAoGAyRWnWFTNq5S062bQKbjuG4Zx7/Tp0wYGBgEBAXUu1Yy6QobKIAaNNusTYfopVySVYPCA5R07dnTp0qVDhw7qPzRDl2xgTEFaXFW9efOma9eu9S3VpDyWIZIIZrbYlBZCQgHTSGTpQMfk6FouPDzc2rreaXw1L4+BdvLw8FCwVDP63VoIOp1OImldx20LsXTp0voGH0MeNw6fz5dKpVhHoY1KSkqeP38um2m3TpDHjWBmZgbtMSbIZPLq1asVrAB53AgVFRU8Hg/rKLSRvr6+j4+PghUgjxvBxARm28bGmTNn7ty5o2AFyONGqK6uLi4uxjoKbXTjxo06p8OSg363RtDT06usrMQ6Cm00c+ZMJycnBStAe9wIZmZm9c3LBFTK1dW1vjtMZSCPG8HS0vL9+/dYR6F1njx5smnTJsXrQB43go2NTX3PCwKq8+DBAwXfSMtAfdwIJiYmKSkppaWl9T2lAqjC6NGjjY2/8WBZaI8bp02bNu/evcM6Cu1iaWkpe5KLApDHjePr65uVlYV1FFrk2rVrf/zxxzdXgzxuHC8vr8uXL2MdhRa5evVq+/btv7maJt0P0kIEBwcfPnz4mxUbUAqpVNqQMS3QHjdaSEjIs2fPsI5CK/B4vKqqqoasCXncaAEBAQomUgBKNG3atJycnIasCXncaC4uLlQqNT4+HutAcC4/P9/Hx0fxbSByUB83xc2bNxMSEmbPno11IOAzaI+bok+fPk+fPoXvqFWHx+NFRzfi6cWQx000Y8aMbdu2YR0Fbq1fv55Ga8ScSZDHTeTv729sbPzq1SusA8EhPp8fFBQ0aNCghm8C9XHTCQSCPn36PHz4EOtAALTHzUCj0ZYuXbp06VKsA8GV+/fvL1++vLFbQR43S3BwMJvNvnnzJtaB4EdMTMySJUsauxXUFUowatSoX3/91dXVFetAtBfksXJ07tz50aNHiu+9AYolJCQkJiaOGDGiCdtCXaEc58+fnzBhAtZRaLCysrLZs2c3LYmhPVam9PT0RYsWnTx5EutANFIDx7XVB9pjpXF0dIyMjBw/fjzWgWie58+f5+fnN2cPkMfK5ObmtmHDhrFjx2IdiCbZuXNnfHz8N+8kVQzqCuVLSEhYtWrViRMnsA5EAwgEApFIpKen18z9QHusfB4eHr/99huMhvum7Ozsp0+fNj+JoT1Wofz8/JCQkMuXL8MdUHV6/PjxsWPHlDXWCvJYhaRSaf/+/devX9+uXTusY2lZqqqqdHV1lbhDqCtUiEQiXbt2bffu3TExMVjH0oJcuXKlqKhIufuEPFa5Xbt2JSUl7du3D+tAWoTCwsJHjx45Ojoqd7dQV6jJuXPnLly4oOXZnJqaymAwmtnFVidoj9UkJCRk+vTp/v7+aWlpWMeCjRkzZtDpdFUkMbTH6iYQCH744Yfw8PDQ0FD5h0OGDDl79iymcalWTU1NYmJiZWWln5+fig4B7bFa0Wi0EydOJCYmRkVFyT7x8fHJz88/dOgQ1qGpypMnT8rKypydnVWXxJDH2Fi6dGm7du3CwsK6d+8u6547f/68goccaq7k5OQjR46w2WxVzxsNeYyNQYMGlZWVyZ9ilpeX16jb3DVCYWGhVCrdvn27Go4FeYyNkJCQiooK+VuhUHj69GlMI1Kmqqqqnj176unptWnTRj1HhDzGRnZ2du23BALh06dP586dwy4iZXr06NHFixfpdLrajgh5jI3u3btbWVkZGxvTaDRZlxGHwzl69CjWcTXXqlWrZLffslgsdR4X+t2UI/ZeReFHgVhQI+BLGr6VRCIRiURCoVAgEIjF4mqptJW9vSrDVK3S0lIymaSnp9/kPRiYUOgskqOnrrl9464LIY+bi1spPbruYxs/Q6Y+Wc9QR1pdjXVEmqyG8CmHX5IntLCnegcYNnw7yONm4VZKz+/OCxxjRWVAhaZMTy4UGVnqePc2aOD6cPab5daxQv8hZpDEStdlkGl+hiAvXdDA9eEX0HSVpZLSApGh2TceiQWaxtSW/j62QQ9VgDxultI8kbUzE+socMvEisarkjZwZcjjphMKpGIhXNWpCpGEKopEDV1ZxcEAoA6QxwAPII8BHkAeAzyAPAZ4AHkM8ADyGOAB5DHAA8hjgAeQxwAPII8BHkAeAzyAPFar5Svmz503FesoMJCRkdYrwCc+PlZF+4c8Bo1z5uzJtetXYB3FlyCPQeOkpiZhHUId4PmbmCkqKty1+/dXr57xBXwbG7uIET8EBvaXLYqPj927f3tqahKBQHBz9Zg0aYabaxuEUPSpI/8c3v/r0tU7dm4qLMw30Dcc+8Pkvn0HfvNY165dPHbiYH5+rrm5ZfiI7/sFD5Z9funy2ZPRh/Pycuh0RudOflOn/MxmGyGEIlcuRAh16uR39NiBkpJPNtZ2s2YucHf3nD3nx7i417Id/rnnSEJC3KF/9s6bs3Tj5qigwAFTp8xW8EOpFLTH2BCLxb8s+Ck75+OqlZv+3n+ye7feq9cue/ToHkIoO/vjvPnTTIxNd2w7sH3r33QGY94vU4uKChFCJBKZy+VERx/etGHXuTO3g4IGrNsQmZX1QfGx7t2/tX7jyuC+g7b+sX/ggND1G1bevXcTIXT9+qWNm6KCAgf8te/EyhUbUt8nL1o8S3bfMYlMjk+ITUpK+HP3kZhTN/T1DdZtiEQIRa3c7OLs2rtX0NmYmw72ThQKRSDgx5w5vmD+ipCQ4Qp+KFWDPMbGs2ePsrI+LJi/ol27DtbWtmN/mOzh0e7M2RMIoXPnT9HpjEULVzo6Ojs6Oi9ZFCWRSK5dvyjbsLq6eszoiUZGxjo6OqNHTaDRaLduX1V8rOhTR7r69wwf8X1rF7fhYaPCR3xfUvxJ9rm/f49RI8fZ2Nh5eXnPmP5L6vvkhIQ42VYCAX/a1Dl0Op1Go/UJ6JeV9UEgELBYLBKZTNHR0dc3IJFIBAJBIBCEDRvp29nf0sJKwQ+lapDH2HiflkylUp0cXeSfuLi4paWnIoRS3ye5OLvKH7nOYDBsbOzS01Plazo7u8peUCgUK0ub3Nzsr3b/H6mpSa1bu8vfTv5x5rBhERKJJD3jvbubp/xz2Tpp/z+QlaUNjUaTvdbV1UMIVVVV1rl/d3fPb/5QqgZ5jA0Ol0Oj0QkEgvwTJoPJ43ERQjwel8n8z6RSjP8vkpGnF0KIRqdXcRTdVCybqYhG+3KqNb6AX1NTw2D8e58sg85ACPH5n6cA1flqptf6pjqRR6vgh1I1yGNssJgsPp9XOzO4/09fJpPF5XJqr8zlcmpnNp/Pl7/m8bh6uoqeo0ij0Wg02tfJRKfRiURi7c+5PG7tpFTuD6VqkMfYaO3iLhKJUt8nyz95l/jW1bWNbFFKapJ8Wu8qTlVW1gfZIpm4uFeyFzweLyvrg41NK8XHcnJq/fbta/nbbTs2btuxkUwmOzm6xCf8+8XEu8S38upCsfoaZgU/lKpBHmOjUyc/Ozv7TZuikpITc/Ny9u7bnpzybnjYKIRQSMhwoVCwfuPK7OyPGRlpUb8tYTJZfYM+d66RSKSjxw/Ex8dmZ3/csnUtQiggIFjxscKGjXzx8unfB3Ynp7w7HXP87NmTbq4eCKHhw0c/ffrwZPThgoL8N7Evt+3Y2K5dB9dv5bEuSzctLeV9WkpFRXnDfyhVg/5jbJDJ5PVrt+/ctXn+gp8EAoGDvdOqyI0d2ndECFlZWm9Yt+PPfdsm/hhBIpE8Pbx+37THwODfSft+nDhj2/YNGZlpJsamqyI3Wll+4wlIPboHzJ618GT04WPHD5qZWcycMb9PQDBCqE9AsFAoOBl9eO++7Uwmq6t/z8mTZ30z8tDQ8DVrl82cNSFyxYaG/1CqBvMUNl3Ky6qMeF7XoWZqO2LMmRM7dm66deO52o6IodJ84ZPzheHzbRuyMtQVAA+grsCDRUtmJyTUPZRsQP/QKQ2oFjQd5LEmGRo6YmjoiK8/X7ggUlLPY8u+7jnGJchjPNBvxqMM8AHqY4AHkMcADyCPAR5AHgM8gDwGeAB5DPAA8hjgAeQxwAPI46YjEBCJDCdQVQhEAplGauDK8GtoOqY+ubK0oQ/GAo3FrRBTaYQGrIggj5uFbU4VCRv6oELQWBUlYgv7hg4OgTxuOjqLaOPMiH9QhnUgOFRTg15eL/YJNGzAugjG0SvBzSNFDAOKZ9eGnnHwTbxKyd2TBX2/NzMwoTRwE8hjJbgfU/wpR0iiEAxNqWIRnM+mo+gQc9M4dCa553cmhqYNTWLIY6WpKpWUFIg45ZJqact94vSRI0d69eplaWmJdSD1otFJbAsdY6svp874Jhh/rBy6bLIuu6WfzL0nk+3a9nZzM8A6EOWD9hjgAfRXaBEOhyORSLCOQiUgj7XI/Pnzk5Ja4izczQd5rEXs7OyYTGYDVtQ8UB8DPID2WItAfQzwYMaMGVAfA41na2tbew5wPIH6GOABtMdapKioSCTC54BpyGMtsmDBgpSUFKyjUAnIYy1iamqqo6ODdRQqAfUxwANoj7VIVlaWQCDAOgqVgDzWIsuXL3///j3WUagE5LEWgf5jAFo0aI+1SH5+vlAoxDoKlYA81iKLFy9OTVXHU8vVD/JYixgbG1MojbgJWYNAfQzwANpjLVJRUQHjj4HGW7NmTXJyMtZRqATksRYpLCzEaxkJ9bEWEYvFZDKZQGjoZKwaBPIY4AHUFVoExh8DPMDx/SBQV2iRnJwcY2NjXA4VgjwGeAB1hRaB+hjgAdTHAA+kUimJ1NAn0mkWyGOAB1BXaJFx48bFx8djHYVKQB4DPIC6QotAfQxAiwZ1hRaZOHEi1MdA40mluH2qO9QV+NehQweEkHzYsew37ujoGB0djXVoSgPtMf65uLgQiUTC/xGJRF1d3UmTJmEdlzJBHuPfiBEjvpgu1tbWNigoCLuIlA/yGP9CQ0Otra3lb5lM5qhRozCNSPkgj7XCyJEjqVSq7LWtrW1wcDDWESkZ5LFWGDJkiJWVlawxHjNmDNbhKB/ksbaIiIigUCitWrXCWWUsA/1uLVF+hqCqTMyrkgr41SJ+tbJ2e+HCBS8vLxsbG6XsjcYkEgiIoUtm6pPN7ag0JpbfeEMetyAZCbz3r6syE7nGNiyxSEqikEkUMmqps02QyESxQFwtlqKa6vJCvoGJjnN7ZhtffSoDgz/ykMctwsd3vPtnihlsOklHR9eUQSJrXr3HKxdyirmcYp5LB1bXECM1Hx3yGHsX9xeWF0uMHYxoLDxM6lryoTw/tSxwtEVrb6baDgp5jKXyT+Kjaz/ad7Si6+PtsXYFSZ9snCj+g9XUMEMeY4bPkR5dn+3Q2ZpAbKklcPOUfii3sCV0GcBWw7Egj7FRWiA6uyvfwde6AetqsOLMcj09SdBoM1UfSPOuJ/Dh6Losh844T2KEkLG9QWU54c2dclUfCPIYAxf2FTj5WbXYDjXlMnY0Sk8U5mXwVXoUyGN1S31VVVVeQ2Ph7cJOAaax7p2TxSo9BOSxuj08V2LioI5Ln5aDrk9FJHJaLEd1h4A8VqvkF5UGliwKnYx1IHWLS7g179fOXK7yy1kTB3bCkyql71YO8lit3j2rojCoWEeBAR0GuaRAVFYkVtH+IY/Vp6Ya5aXzdU0YWAeCDZYRIzNBVaVFC/0Dh0sfkrhmjnqq239OXvLlGztz8pKlErGzY8fB/X5mG1oghA4dX0wgoNbOXe7cP1RR9cnU2C504Dw7G0+EkFQqOXf599dvr9ZUV7u37urk4KO68PRMmfkfVFVaQHusPuVFYqlUVZ1tZeUFu/+aRiQQp47fOWX8Dh6vcs+B6WKJCCFEIpEzP8ZlZSfOnnZoxYKrDIb+iZgo2Va37x989vLs4H6zf552yL6V1817f6koPIQQmUrOz+CpaOeQx+pTVS4h66hqkO6TFzGIQBg1fJWFmZONlXtE2IrSstz4xNuypSIRf3C/2VQduo4OrUPb4KLiDyKRACH0Ku6Kh3uPTh0GGRvZ+HUa5uLYWUXhIYQoVJKAq6oJNCCP1aeqTEKhqaqQy8pOsLVyp9N1ZW8NDczZhla5+amyt8ZGNjo6nx8LwqDrIYR4/EqJRFX4aT4AAANXSURBVFxckm1j5S7fia11GxWFhxBCBKRDI/GqVJLKUB+rD1GVD2DkC7h5BSkLVnSVfyKViiurPn/7QCZ/3UlSIxLxEUKUWouoVNVegxKISEXnAPJYfZj6JG6Rqh5TTqMx7W29wkIW1v5QR0dRXlJ0aAghvvDfPgQ+X4VdvAghIU9KZ6mksoK6Qn1YBiSJSFUFop2NR3FpthHb2tSklewfQgQ9XWMFm1DIOoYGFvkF7+WfpKY/V1F4CCGJUKq6e/ggj9XH0JSqQ1HVKFlfn1ChkHc8ZmVuXsqn4qwbd/Zv3B6RnZuoeKv2nkEJ7+49fXk2vyDt3qMjef+vp1VBLJBYOqqqboG6Qn3s3BiX/85jt1LJLRJsQ4sp43deur59x74fiUSSuanjuFEbZZ3ECgT2nsjllV+8urW6ptrNxX9A0PRDJxZV1yjtDu3aOMVcBzdVjY6CcfRqdWZnHllXT9eYjnUgGMh4lhM61cLQTCWpDHWFWrl11BVxBFhHgQExX8o2o6ooiaGuUDfXjrqPLpTometRaHVf8bxLfnj09PI6FzHp+lx+RZ2LfL2HDAyeoawgMz/G7j88t85F1dVSYj2dZ4pj+JRR0qmPrrIi/BrUFeqW8rLq9X2uhZtJnUtFIgGHW1rfIvl3GV+gUplMhr6yIhSLhVWckvoWkUgUIrGOP+MKYuBXiso+FI9coJx5jOoEeYyBS/sLKAYGOgw8zFbREGUfSjoF6lo5qfCqAOpjDAyYYJ76MAfrKNSkJLPUrjVFpUkMeYyZiPm2Gc/wn8olH8pZutUdehuq+kBQV2CGWyk5sSnXobM1Xm+cLs0qN7ck+A1Sx82I0B5jhqlHDp1mkXAzU1AlwjoW5StK/WRqXqOeJIb2uEW4eqCgrLia3YpNZeLhyq80uyIvqTT4e3On9iy1HRTyuEXITOA+OFvMMmYQdXT0TJlEkuaVGvwKIaeYxynhOrdj+ocYq3KMah0gj1uQjLfc1DeczASOaStdsaiapEMiUSgtdhZDApEgFYqlYmlNdXVFEV/XkOzsxXLvos9gwTzeACGEUG66oKpEzK2UCHjVQn4LfZguQ5eMUA1TT/ZcBRpDD56rAEDzQH8FwAPIY4AHkMcADyCPAR5AHgM8gDwGePA/Ww2RKg5Q/iUAAAAASUVORK5CYII=",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "#### Use langchain multiple tools by agent and action, also show config file\n",
    "###https://medium.com/@astropomeai/advanced-multi-agent-ai-system-implementing-iterative-processing-feedback-loops-and-evaluation-b9cccfc4c9d1\n",
    "from langchain import OpenAI, LLMMathChain, SerpAPIWrapper\n",
    "from langchain.chat_models import ChatOpenAI\n",
    "from langchain.chains.conversation.memory import ConversationBufferWindowMemory\n",
    "from langchain.agents import initialize_agent, Tool, AgentType\n",
    "from langchain.tools import BaseTool\n",
    "from langgraph.graph import StateGraph, MessagesState, START, END\n",
    "from langgraph.graph.message import add_messages\n",
    "from langgraph.prebuilt import ToolNode\n",
    "from langchain_anthropic import ChatAnthropic\n",
    "from langchain_core.tools import tool\n",
    "#from langgraph.checkpoint import Checkpointer\n",
    "from langgraph.checkpoint.memory import MemorySaver\n",
    "from typing import List, TypedDict, Annotated, Literal\n",
    "import operator\n",
    "\n",
    "from langchain_anthropic import ChatAnthropic\n",
    "from langchain_google_genai import ChatGoogleGenerativeAI\n",
    "from langchain_openai import ChatOpenAI\n",
    "from langgraph.graph import StateGraph, START, END\n",
    "from langgraph.graph.message import add_messages\n",
    "from pydantic import BaseModel\n",
    "from langchain.schema import HumanMessage, AIMessage\n",
    "import json, os\n",
    "import requests\n",
    "import pandas as pd\n",
    "from typing import Annotated\n",
    "from typing_extensions import TypedDict\n",
    "from langgraph.checkpoint.memory import MemorySaver\n",
    "from langchain.memory import ConversationBufferMemory\n",
    "import uuid\n",
    "from typing import Literal, Dict, List\n",
    "memory = MemorySaver()\n",
    "\n",
    "API_KEY = ''\n",
    "from langchain.tools import tool\n",
    "\n",
    "os.environ['OPENAI_API_KEY']=API_KEY\n",
    "def create_llm(model_class, model_name, temperature=0.7):\n",
    "    return model_class(model=model_name, temperature=temperature)\n",
    "\n",
    "# Initialize LLM models\n",
    "#claude = create_llm(ChatAnthropic, \"claude-3-haiku-20240307\")\n",
    "#gemini = create_llm(ChatGoogleGenerativeAI, \"gemini-1.5-flash-latest\")\n",
    "#deepseek = ChatOpenAI(model=\"deepseek-chat\", temperature=0, openai_api_key=Deepseek_key, openai_api_base='https://api.deepseek.com')\n",
    "openai = create_llm(ChatOpenAI, \"gpt-4o\")\n",
    "reviewer = create_llm(ChatOpenAI, \"gpt-4o\")\n",
    "\n",
    "from langgraph.graph import END, StateGraph\n",
    "from typing import List, Tuple\n",
    "\n",
    "class AgentState(TypedDict):\n",
    "    focus_areas: List[str]\n",
    "    research_goal: str\n",
    "    research_observations: List[str]\n",
    "    hypotheses_and_proposals: List[Tuple[str, str]]\n",
    "    hypotheses_and_proposals_with_scores: List[Tuple[str, str, float]]\n",
    "    ranked_hypotheses: List[Tuple[str, str, float]]\n",
    "    messages: Annotated[List[HumanMessage], add_messages]\n",
    "    iteration: int\n",
    "    expected_result: str\n",
    "    feedback: str\n",
    "    agent_outputs: Annotated[List[AIMessage], add_messages]\n",
    "    evaluation: float\n",
    "    continue_loop: bool  # Flag to continue the loop\n",
    "\n",
    "class Node:\n",
    "    def __init__(self, name: str):\n",
    "        self.name = name\n",
    "\n",
    "    def process(self, state: AgentState) -> dict:\n",
    "        raise NotImplementedError\n",
    "\n",
    "    def __call__(self, state: AgentState) -> dict:\n",
    "        result = self.process(state)\n",
    "        print(f\"{self.name}: Processing complete\")\n",
    "        return result\n",
    "\n",
    "\n",
    "class SupervisorAgent:\n",
    "    def __init__(self):\n",
    "        self.name = \"Supervisor\"\n",
    "\n",
    "    def __call__(self, state):\n",
    "        \"\"\"\n",
    "        Extract research topic from human input and set expected result.\n",
    "        \"\"\"\n",
    "        if state.get('messages'):\n",
    "            research_topic = state['messages'][0].content\n",
    "            state['research_topics'] = [research_topic]\n",
    "            # Set expected result dynamically based on input topic\n",
    "            state['expected_result'] = (\n",
    "                f\"Provide an in-depth analysis of the topic: {research_topic}, \"\n",
    "                \"including relevant scientific theories, recent studies, and philosophical perspectives.\"\n",
    "            )\n",
    "        else:\n",
    "            state['research_topics'] = [\"Default research topic\"]\n",
    "            state['expected_result'] = \"Provide a general analysis of the given research topic.\"\n",
    "        return state\n",
    "\n",
    "\n",
    "class AgentNode(Node):\n",
    "    def __init__(self, agent_name: str, llm):\n",
    "        super().__init__(agent_name)\n",
    "        self.llm = llm\n",
    "\n",
    "    def process(self, state: AgentState) -> dict:\n",
    "        task = state['messages'][-1].content\n",
    "        feedback = state.get('feedback', '')\n",
    "        if feedback:\n",
    "            task += f\"\\nFeedback: {feedback}\"\n",
    "        prompt = f\"You are {self.name}. Please perform the following task: {task}\"\n",
    "        response = self.llm(messages=[HumanMessage(role=\"user\", content=prompt)])\n",
    "        agent_output = AIMessage(role=\"assistant\", content=f\"{self.name} response: {response.content}\")\n",
    "        state['agent_outputs'].append(agent_output)\n",
    "        return {\"messages\": [agent_output], \"agent_outputs\": [agent_output]}\n",
    "\n",
    "\n",
    "   \n",
    "class HypothesisGenerationAgent:\n",
    "    def __init__(self, llm):\n",
    "        self.name = \"Hypothesis Generator\"\n",
    "        self.llm = llm\n",
    "\n",
    "    def __call__(self, state):\n",
    "        \"\"\"\n",
    "        Generate hypotheses based on research topics and previous feedback.\n",
    "        \"\"\"\n",
    "        research_topics = state.get('research_topics', [])\n",
    "        feedback = state.get('feedback', '')\n",
    "\n",
    "        # Generate new hypotheses considering feedback\n",
    "        hypotheses = self.generate_hypotheses(research_topics, feedback)\n",
    "\n",
    "        # Ensure 'agent_outputs' contains role and content keys\n",
    "        if 'agent_outputs' not in state:\n",
    "            state['agent_outputs'] = []\n",
    "\n",
    "        if hypotheses:  # Only append if hypotheses are not empty\n",
    "            hypothesis_text = \"\\n\".join(\n",
    "                [f\"Topic: {h['Topic']}\\nHypothesis: {h['Hypothesis']}\" for h in hypotheses]\n",
    "            )\n",
    "            # Add hypothesis output in the correct format\n",
    "            state['agent_outputs'].append({\n",
    "                \"role\": \"assistant\",\n",
    "                \"content\": f\"{self.name} generated the following hypotheses:\\n{hypothesis_text}\"\n",
    "            })\n",
    "        else:\n",
    "            # Add fallback output if no hypotheses are generated\n",
    "            state['agent_outputs'].append({\n",
    "                \"role\": \"assistant\",\n",
    "                \"content\": f\"{self.name} did not generate any hypotheses.\"\n",
    "            })\n",
    "\n",
    "        return state\n",
    "\n",
    "    def generate_hypotheses(self, research_topics, feedback):\n",
    "        topics_text = \"\\n\".join(research_topics)\n",
    "        feedback_text = f\"\\nPrevious Feedback: {feedback}\" if feedback else \"\"\n",
    "\n",
    "        prompt = (\n",
    "            f\"Research Topics:\\n{topics_text}\\n\\n\"\n",
    "            f\"{feedback_text}\\n\\n\"\n",
    "            \"\"\"For each research topic, generate a well-structured scientific hypothesis.\n",
    "             You are an domain expert tasked with formulating a novel and robust hypothesis.  \n",
    "            \n",
    "             Search AML cell lines or AML disease often exhibit upregulated pathways with preclinical evidence \n",
    "             \n",
    "             Identify a drug will downregulated key regulators or enzymes for any of the up-regulated pathways  with preclinical evidence.\n",
    "                               \n",
    "             The ultimate goal is have a completely novel repurposing the drug for AML\n",
    "             \n",
    "             You have conducted a thorough review of relevant literature and developed a logical framework\n",
    "             for addressing the objective. The articles consulted, along with your analytical reasoning,\n",
    "             are provided below.\n",
    "             Goal: {goal}\n",
    "             {preferences}\n",
    "             Existing hypothesis (if applicable):\n",
    "             {source_hypothesis}\n",
    "             {instructions}\n",
    "             Literature review and analytical rationale (chronologically ordered, beginning\n",
    "             with the most recent analysis):\n",
    "             {articles_with_reasoning}\n",
    "             Proposed hypothesis (detailed description for domain experts)\n",
    "            Ensure the hypotheses are testable and based on existing scientific principles.\\n\\n\"\"\"\n",
    "            \"Format:\\n- Topic: <topic>\\n  Hypothesis: <hypothesis>\"\n",
    "        )\n",
    "\n",
    "        response = self.llm(prompt)\n",
    "        response_content = response if isinstance(response, str) else response.content\n",
    "        return self.parse_hypotheses(response_content)\n",
    "\n",
    "    def parse_hypotheses(self, content):\n",
    "        lines = content.splitlines()\n",
    "        hypotheses = []\n",
    "        current_topic = None\n",
    "        for line in lines:\n",
    "            if line.startswith(\"- Topic:\"):\n",
    "                current_topic = line.replace(\"- Topic:\", \"\").strip()\n",
    "            elif line.startswith(\"  Hypothesis:\") and current_topic:\n",
    "                hypothesis = line.replace(\"  Hypothesis:\", \"\").strip()\n",
    "                hypotheses.append({\"Topic\": current_topic, \"Hypothesis\": hypothesis})\n",
    "        return hypotheses\n",
    "\n",
    "\n",
    "class ReviewerNode:\n",
    "    def __init__(self, llm):\n",
    "        self.name = \"Reviewer\"\n",
    "        self.llm = llm\n",
    "\n",
    "    def __call__(self, state):\n",
    "        expected_result = state.get('expected_result', '')\n",
    "\n",
    "        # âœ… Debug print to check if state is being passed\n",
    "        print(f\"\\n--- State in ReviewerNode ---\\n{state}\\n\")\n",
    "\n",
    "        # Collect outputs from agent_outputs\n",
    "        agent_outputs = state.get('agent_outputs', [])\n",
    "        if not agent_outputs:\n",
    "            state['feedback'] = \"The agent output is missing.\"\n",
    "            return state\n",
    "\n",
    "        # Extract agent outputs in the correct format\n",
    "        agent_outputs_text = \"\\n\".join([f\"{output.get('role', 'unknown')}: {output.get('content', '')}\" for output in agent_outputs])\n",
    "\n",
    "        # Generate review feedback\n",
    "        review_prompt = (\n",
    "            f\"Expected result:\\n{expected_result}\\n\\n\"\n",
    "            f\"Agent outputs:\\n{agent_outputs_text}\\n\\n\"\n",
    "            \"Please compare the expected result with the agent outputs, \"\n",
    "            \"and provide feedback and an evaluation score between 0 and 1.\\n\"\n",
    "            \"Format:\\nFeedback: ...\\nEvaluation Score: 0.X\"\n",
    "        )\n",
    "\n",
    "        response = self.llm(review_prompt)\n",
    "\n",
    "        # Extract content if response is an AIMessage object\n",
    "        response_content = response.content if hasattr(response, 'content') else str(response)\n",
    "\n",
    "        feedback, evaluation = self.parse_feedback_and_evaluation(response_content)\n",
    "        state['feedback'] = feedback\n",
    "        state['evaluation'] = evaluation\n",
    "        return state\n",
    "    def parse_feedback_and_evaluation(self, content):\n",
    "        \"\"\"\n",
    "        Parses the feedback and evaluation from the LLM response.\n",
    "        \"\"\"\n",
    "        lines = content.splitlines()\n",
    "        feedback = ''\n",
    "        evaluation = 0.0\n",
    "        for line in lines:\n",
    "            if line.startswith(\"Feedback:\"):\n",
    "                feedback = line.replace(\"Feedback:\", \"\").strip()\n",
    "            elif line.startswith(\"Evaluation Score:\"):\n",
    "                score_str = line.replace(\"Evaluation Score:\", \"\").strip()\n",
    "                try:\n",
    "                    evaluation = float(score_str)\n",
    "                except ValueError:\n",
    "                    evaluation = 0.0\n",
    "        return feedback, evaluation\n",
    "\n",
    "class ReviewerNode:\n",
    "    \n",
    "    def __init__(self, llm):\n",
    "        self.name = \"Reviewer\"\n",
    "        self.llm = llm\n",
    "\n",
    "    def __call__(self, state):\n",
    "        expected_result = state.get('expected_result', '')\n",
    "\n",
    "        # Collect outputs from agent_outputs\n",
    "        agent_outputs = state.get('agent_outputs', [])\n",
    "        if not agent_outputs:\n",
    "            state['feedback'] = \"The agent output is missing.\"\n",
    "            return state\n",
    "\n",
    "        # Extract agent outputs in the correct format\n",
    "        agent_outputs_text = \"\"\n",
    "        for output in agent_outputs:\n",
    "            if hasattr(output, 'role') and hasattr(output, 'content'):\n",
    "                # If output is an AIMessage object\n",
    "                agent_outputs_text += f\"{output.role}: {output.content}\\n\"\n",
    "            elif isinstance(output, dict):\n",
    "                # If output is a dictionary\n",
    "                agent_outputs_text += f\"{output.get('role', 'unknown')}: {output.get('content', '')}\\n\"\n",
    "            else:\n",
    "                # Handle unknown output format\n",
    "                agent_outputs_text += f\"Unknown format: {str(output)}\\n\"\n",
    "\n",
    "        # Generate review feedback\n",
    "        review_prompt = (\n",
    "            f\"Expected result:\\n{expected_result}\\n\\n\"\n",
    "            f\"Agent outputs:\\n{agent_outputs_text}\\n\\n\"\n",
    "            \"Please compare the expected result with the agent outputs, \"\n",
    "            \"and provide feedback and an evaluation score between 0 and 1.\\n\"\n",
    "            \"Format:\\nFeedback: ...\\nEvaluation Score: 0.X\"\n",
    "        )\n",
    "\n",
    "        response = self.llm(review_prompt)\n",
    "\n",
    "        # Extract content if response is an AIMessage object\n",
    "        response_content = response.content if hasattr(response, 'content') else str(response)\n",
    "\n",
    "        feedback, evaluation = self.parse_feedback_and_evaluation(response_content)\n",
    "        state['feedback'] = feedback\n",
    "        state['evaluation'] = evaluation\n",
    "        return state\n",
    "\n",
    "    \n",
    "    \n",
    "\n",
    "    \n",
    "    def parse_feedback_and_evaluation(self, content):\n",
    "        \"\"\"\n",
    "        Parses the feedback and evaluation from the LLM response.\n",
    "        \"\"\"\n",
    "        lines = content.splitlines()\n",
    "        feedback = ''\n",
    "        evaluation = 0.0\n",
    "        for line in lines:\n",
    "            if line.startswith(\"Feedback:\"):\n",
    "                feedback = line.replace(\"Feedback:\", \"\").strip()\n",
    "            elif line.startswith(\"Evaluation Score:\"):\n",
    "                score_str = line.replace(\"Evaluation Score:\", \"\").strip()\n",
    "                try:\n",
    "                    evaluation = float(score_str)\n",
    "                except ValueError:\n",
    "                    evaluation = 0.0\n",
    "        return feedback, evaluation\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "class LoopControlNode:\n",
    "    def __init__(self, max_iterations):\n",
    "        self.max_iterations = max_iterations\n",
    "\n",
    "    def __call__(self, state):\n",
    "        # Increment iteration count\n",
    "        state['iteration'] += 1\n",
    "\n",
    "        # Print the output of each iteration\n",
    "        print(f\"\\n===== Iteration {state['iteration']} =====\")\n",
    "        print(\"Expected Result:\", state.get('expected_result', 'N/A'))\n",
    "\n",
    "        # Handle different output formats\n",
    "        agent_outputs = state.get('agent_outputs', [])\n",
    "        if agent_outputs:\n",
    "            for output in agent_outputs:\n",
    "                if hasattr(output, 'role') and hasattr(output, 'content'):\n",
    "                    # If output is an AIMessage object\n",
    "                    print(f\"Agent Output from {output.role}: {output.content}\")\n",
    "                elif isinstance(output, dict):\n",
    "                    # If output is a dictionary\n",
    "                    print(f\"Agent Output from {output.get('agent_name', 'Unknown Agent')}: {output.get('output', '')}\")\n",
    "                else:\n",
    "                    # Unknown format\n",
    "                    print(f\"Unknown output format: {output}\")\n",
    "        else:\n",
    "            print(\"No agent outputs yet.\")\n",
    "\n",
    "        # Print feedback and evaluation\n",
    "        print(\"Feedback:\", state.get('feedback', 'No feedback'))\n",
    "        print(\"Evaluation Score:\", state.get('evaluation', 0.0))\n",
    "        print(\"===================================\\n\")\n",
    "\n",
    "        # Continue loop until reaching the maximum number of iterations\n",
    "        if state['iteration'] < self.max_iterations:\n",
    "            state['continue_loop'] = True\n",
    "        else:\n",
    "            state['continue_loop'] = False\n",
    "        return state\n",
    "\n",
    "\n",
    "class AgentNode:\n",
    "    def __init__(self, name, llm):\n",
    "        self.name = name\n",
    "        self.llm = llm\n",
    "\n",
    "    def __call__(self, state):\n",
    "        task = state.get('task', 'No task provided.')\n",
    "        response = self.llm(f\"{self.name} responding to: {task}\")\n",
    "        state[f\"{self.name}_output\"] = response\n",
    "        return state\n",
    "\n",
    "\n",
    "\n",
    "# Initial state with iteration count\n",
    "initial_state = AgentState(\n",
    "    messages=[HumanMessage(role=\"user\", content=\" Suggest an existing drug that could be repurposed for acute myeloid leukemia (AML)treatment The drug should inhibit the proliferation of AML cell lines\")], \n",
    "    iteration=0,\n",
    "    expected_result=\"Criteria for a strong hypothesis for a drug treatment for AML\",\n",
    "    feedback=\"\",\n",
    "    agent_outputs=[],\n",
    "    evaluation=0.0,\n",
    "    continue_loop=True\n",
    ")\n",
    "\n",
    "# Simulate a workflow step for testing\n",
    "hypothesis_agent = HypothesisGenerationAgent(llm=openai)  # Replace mock_llm with your actual LLM\n",
    "reviewer = ReviewerNode(llm=openai)\n",
    "\n",
    "# Pass state through agents\n",
    "state = hypothesis_agent(initial_state)\n",
    "state = reviewer(state)\n",
    "\n",
    "\n",
    "builder = StateGraph(AgentState)\n",
    "\n",
    "nodes = {\n",
    "   # \"supervisor\": SupervisorNode(),\n",
    "    \"supervisor\": SupervisorAgent(),\n",
    "    \"Hypothesis Generator\":HypothesisGenerationAgent(openai),\n",
    "   # \"agent1\": AgentNode(\"Agent1 (Claude)\", openai),\n",
    "   # \"agent2\": AgentNode(\"Agent2 (Gemini)\", openai),\n",
    "   # \"agent3\": AgentNode(\"Agent3 (GPT-4)\", openai),\n",
    "    \"reviewer\": ReviewerNode(openai),\n",
    "    \"loop_control\": LoopControlNode(max_iterations=5)\n",
    "}\n",
    "\n",
    "for name, node in nodes.items():\n",
    "    builder.add_node(name, node)\n",
    "\n",
    "\n",
    "\n",
    "# Define the flow\n",
    "builder.add_edge(START, \"supervisor\")\n",
    "\n",
    "# Edges from Supervisor to Agents\n",
    "builder.add_edge(\"supervisor\", \"Hypothesis Generator\")\n",
    "#builder.add_edge(\"supervisor\", \"agent2\")\n",
    "#builder.add_edge(\"supervisor\", \"agent3\")\n",
    "\n",
    "# Edges from Agents to Reviewer\n",
    "builder.add_edge(\"Hypothesis Generator\", \"reviewer\")\n",
    "#builder.add_edge(\"agent2\", \"reviewer\")\n",
    "#builder.add_edge(\"agent3\", \"reviewer\")\n",
    "\n",
    "# Edge from Reviewer to Loop Control Node\n",
    "builder.add_edge(\"reviewer\", \"loop_control\")\n",
    "\n",
    "# Conditionally decide the next node from Loop Control Node\n",
    "def next_node(state: AgentState) -> Literal[\"supervisor\", END]:\n",
    "    if state['continue_loop']:\n",
    "        return \"supervisor\"\n",
    "    else:\n",
    "        return END\n",
    "\n",
    "builder.add_conditional_edges(\"loop_control\", next_node)\n",
    "\n",
    "# Compile the graph\n",
    "graph = builder.compile()\n",
    "\n",
    "from IPython.display import Image, display\n",
    "try:\n",
    "    display(Image(graph.get_graph().draw_mermaid_png()))\n",
    "except Exception:\n",
    "    # This requires some extra dependencies and is optional\n",
    "    pass\n",
    "\n",
    "#SupervisorNode.invoke(initiate_state)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "111ff578-8e54-4272-be3a-989fcd0fb40e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Agent Outputs in State Before Reviewer:\n",
      "{'role': 'assistant', 'content': 'Hypothesis Generator did not generate any hypotheses.'}\n"
     ]
    }
   ],
   "source": [
    "# Debug print after hypothesis generation\n",
    "print(\"Agent Outputs in State Before Reviewer:\")\n",
    "for output in state['agent_outputs']:\n",
    "    print(output) \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "b40ba60d-5a2b-4e75-b973-039a8a61b6f0",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "===== Iteration 1 =====\n",
      "Expected Result: Provide an in-depth analysis of the topic:  Suggest an existing drug that could be repurposed for acute myeloid leukemia (AML)treatment The drug should inhibit the proliferation of AML cell lines, including relevant scientific theories, recent studies, and philosophical perspectives.\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='1db90a4f-5cb2-4bc0-a7c4-d62be302a7b2'\n",
      "Unknown output format: content='Hypothesis Generator generated the following hypotheses:\\nTopic: Targeting the FLT3 Pathway in AML\\nHypothesis: Inhibition of the FLT3 receptor tyrosine kinase using the drug midostaurin will lead to a significant decrease in the proliferation of AML cells harboring FLT3-ITD mutations, due to its ability to downregulate the hyperactivated FLT3 signaling pathway, thereby reducing downstream activation of STAT5 and MAPK pathways. This effect will be more pronounced in cell lines with higher expression levels of FLT3-ITD, supporting the potential repurposing of midostaurin as a targeted therapy for FLT3-ITD-positive AML.\\nTopic: Repurposing MEK Inhibitors for AML\\nHypothesis: The MEK1/2 inhibitor trametinib will effectively reduce the survival and proliferation of AML cells exhibiting hyperactivation of the MAPK/ERK pathway, commonly seen in AML patients with RAS mutations. By downregulating the MAPK/ERK signaling cascade, trametinib will induce apoptosis and cell cycle arrest in these cells, providing a rationale for its repurposing as a treatment option for RAS-mutated AML.\\nTopic: Targeting Metabolic Pathways in AML\\nHypothesis: Inhibition of the IDH2 enzyme using the drug enasidenib will result in a significant decrease in the production of the oncometabolite 2-hydroxyglutarate (2-HG) in AML cells with IDH2 mutations. This reduction will lead to the restoration of normal histone and DNA methylation patterns, thereby promoting differentiation and apoptosis of the leukemic cells, supporting the repurposing of enasidenib for IDH2-mutant AML.\\nTopic: Exploiting Epigenetic Modulators in AML\\nHypothesis: The BET bromodomain inhibitor JQ1 will downregulate the expression of MYC and other oncogenes in AML cells with elevated MYC levels, leading to reduced cell proliferation and increased apoptosis. This effect will be more pronounced in AML subtypes characterized by MYC overexpression, suggesting the potential repurposing of JQ1 as a therapeutic strategy for MYC-driven AML.\\nTopic: Targeting Apoptotic Pathways in AML\\nHypothesis: The BCL-2 inhibitor venetoclax, in combination with azacitidine, will synergistically induce apoptosis in AML cells by disrupting BCL-2-mediated survival pathways and enhancing the pro-apoptotic effects of azacitidine. This combination therapy will be particularly effective in AML patients with overexpression of BCL-2, providing a novel approach for the treatment of apoptosis-resistant AML.' additional_kwargs={} response_metadata={} id='d5bc200e-a0d6-46ef-8342-5f79197bae77'\n",
      "Unknown output format: content='Hypothesis Generator generated the following hypotheses:\\nTopic: Targeting the FLT3 Pathway in AML\\nHypothesis: Inhibition of the FLT3 receptor tyrosine kinase using the drug midostaurin will lead to a significant decrease in the proliferation of AML cells harboring FLT3-ITD mutations, due to its ability to downregulate the hyperactivated FLT3 signaling pathway, thereby reducing downstream activation of STAT5 and MAPK pathways. This effect will be more pronounced in cell lines with higher expression levels of FLT3-ITD, supporting the potential repurposing of midostaurin as a targeted therapy for FLT3-ITD-positive AML.\\nTopic: Repurposing MEK Inhibitors for AML\\nHypothesis: The MEK1/2 inhibitor trametinib will effectively reduce the survival and proliferation of AML cells exhibiting hyperactivation of the MAPK/ERK pathway, commonly seen in AML patients with RAS mutations. By downregulating the MAPK/ERK signaling cascade, trametinib will induce apoptosis and cell cycle arrest in these cells, providing a rationale for its repurposing as a treatment option for RAS-mutated AML.\\nTopic: Targeting Metabolic Pathways in AML\\nHypothesis: Inhibition of the IDH2 enzyme using the drug enasidenib will result in a significant decrease in the production of the oncometabolite 2-hydroxyglutarate (2-HG) in AML cells with IDH2 mutations. This reduction will lead to the restoration of normal histone and DNA methylation patterns, thereby promoting differentiation and apoptosis of the leukemic cells, supporting the repurposing of enasidenib for IDH2-mutant AML.\\nTopic: Exploiting Epigenetic Modulators in AML\\nHypothesis: The BET bromodomain inhibitor JQ1 will downregulate the expression of MYC and other oncogenes in AML cells with elevated MYC levels, leading to reduced cell proliferation and increased apoptosis. This effect will be more pronounced in AML subtypes characterized by MYC overexpression, suggesting the potential repurposing of JQ1 as a therapeutic strategy for MYC-driven AML.\\nTopic: Targeting Apoptotic Pathways in AML\\nHypothesis: The BCL-2 inhibitor venetoclax, in combination with azacitidine, will synergistically induce apoptosis in AML cells by disrupting BCL-2-mediated survival pathways and enhancing the pro-apoptotic effects of azacitidine. This combination therapy will be particularly effective in AML patients with overexpression of BCL-2, providing a novel approach for the treatment of apoptosis-resistant AML.' additional_kwargs={} response_metadata={} id='56a72377-d70c-4252-b047-035ffcdb34dc'\n",
      "Feedback: The agent outputs provide several hypotheses for repurposing existing drugs for the treatment of acute myeloid leukemia (AML). These include the use of midostaurin, trametinib, enasidenib, JQ1, and venetoclax, each targeting different pathways or mutations relevant to AML. The outputs align with the expected result by suggesting existing drugs and including relevant scientific theories such as FLT3 signaling, MAPK/ERK pathway, IDH2 mutations, MYC expression, and BCL-2 pathways. However, the expected result calls for an in-depth analysis, including recent studies and philosophical perspectives, which are not fully addressed in the agent outputs. The outputs are more hypothesis-driven than analysis-driven, lacking detailed discussion on recent studies or philosophical considerations.\n",
      "Evaluation Score: 0.7\n",
      "===================================\n",
      "\n",
      "\n",
      "===== Iteration 2 =====\n",
      "Expected Result: Provide an in-depth analysis of the topic:  Suggest an existing drug that could be repurposed for acute myeloid leukemia (AML)treatment The drug should inhibit the proliferation of AML cell lines, including relevant scientific theories, recent studies, and philosophical perspectives.\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='1db90a4f-5cb2-4bc0-a7c4-d62be302a7b2'\n",
      "Unknown output format: content='Hypothesis Generator generated the following hypotheses:\\nTopic: Targeting the FLT3 Pathway in AML\\nHypothesis: Inhibition of the FLT3 receptor tyrosine kinase using the drug midostaurin will lead to a significant decrease in the proliferation of AML cells harboring FLT3-ITD mutations, due to its ability to downregulate the hyperactivated FLT3 signaling pathway, thereby reducing downstream activation of STAT5 and MAPK pathways. This effect will be more pronounced in cell lines with higher expression levels of FLT3-ITD, supporting the potential repurposing of midostaurin as a targeted therapy for FLT3-ITD-positive AML.\\nTopic: Repurposing MEK Inhibitors for AML\\nHypothesis: The MEK1/2 inhibitor trametinib will effectively reduce the survival and proliferation of AML cells exhibiting hyperactivation of the MAPK/ERK pathway, commonly seen in AML patients with RAS mutations. By downregulating the MAPK/ERK signaling cascade, trametinib will induce apoptosis and cell cycle arrest in these cells, providing a rationale for its repurposing as a treatment option for RAS-mutated AML.\\nTopic: Targeting Metabolic Pathways in AML\\nHypothesis: Inhibition of the IDH2 enzyme using the drug enasidenib will result in a significant decrease in the production of the oncometabolite 2-hydroxyglutarate (2-HG) in AML cells with IDH2 mutations. This reduction will lead to the restoration of normal histone and DNA methylation patterns, thereby promoting differentiation and apoptosis of the leukemic cells, supporting the repurposing of enasidenib for IDH2-mutant AML.\\nTopic: Exploiting Epigenetic Modulators in AML\\nHypothesis: The BET bromodomain inhibitor JQ1 will downregulate the expression of MYC and other oncogenes in AML cells with elevated MYC levels, leading to reduced cell proliferation and increased apoptosis. This effect will be more pronounced in AML subtypes characterized by MYC overexpression, suggesting the potential repurposing of JQ1 as a therapeutic strategy for MYC-driven AML.\\nTopic: Targeting Apoptotic Pathways in AML\\nHypothesis: The BCL-2 inhibitor venetoclax, in combination with azacitidine, will synergistically induce apoptosis in AML cells by disrupting BCL-2-mediated survival pathways and enhancing the pro-apoptotic effects of azacitidine. This combination therapy will be particularly effective in AML patients with overexpression of BCL-2, providing a novel approach for the treatment of apoptosis-resistant AML.' additional_kwargs={} response_metadata={} id='d5bc200e-a0d6-46ef-8342-5f79197bae77'\n",
      "Unknown output format: content='Hypothesis Generator generated the following hypotheses:\\nTopic: Targeting the FLT3 Pathway in AML\\nHypothesis: Inhibition of the FLT3 receptor tyrosine kinase using the drug midostaurin will lead to a significant decrease in the proliferation of AML cells harboring FLT3-ITD mutations, due to its ability to downregulate the hyperactivated FLT3 signaling pathway, thereby reducing downstream activation of STAT5 and MAPK pathways. This effect will be more pronounced in cell lines with higher expression levels of FLT3-ITD, supporting the potential repurposing of midostaurin as a targeted therapy for FLT3-ITD-positive AML.\\nTopic: Repurposing MEK Inhibitors for AML\\nHypothesis: The MEK1/2 inhibitor trametinib will effectively reduce the survival and proliferation of AML cells exhibiting hyperactivation of the MAPK/ERK pathway, commonly seen in AML patients with RAS mutations. By downregulating the MAPK/ERK signaling cascade, trametinib will induce apoptosis and cell cycle arrest in these cells, providing a rationale for its repurposing as a treatment option for RAS-mutated AML.\\nTopic: Targeting Metabolic Pathways in AML\\nHypothesis: Inhibition of the IDH2 enzyme using the drug enasidenib will result in a significant decrease in the production of the oncometabolite 2-hydroxyglutarate (2-HG) in AML cells with IDH2 mutations. This reduction will lead to the restoration of normal histone and DNA methylation patterns, thereby promoting differentiation and apoptosis of the leukemic cells, supporting the repurposing of enasidenib for IDH2-mutant AML.\\nTopic: Exploiting Epigenetic Modulators in AML\\nHypothesis: The BET bromodomain inhibitor JQ1 will downregulate the expression of MYC and other oncogenes in AML cells with elevated MYC levels, leading to reduced cell proliferation and increased apoptosis. This effect will be more pronounced in AML subtypes characterized by MYC overexpression, suggesting the potential repurposing of JQ1 as a therapeutic strategy for MYC-driven AML.\\nTopic: Targeting Apoptotic Pathways in AML\\nHypothesis: The BCL-2 inhibitor venetoclax, in combination with azacitidine, will synergistically induce apoptosis in AML cells by disrupting BCL-2-mediated survival pathways and enhancing the pro-apoptotic effects of azacitidine. This combination therapy will be particularly effective in AML patients with overexpression of BCL-2, providing a novel approach for the treatment of apoptosis-resistant AML.' additional_kwargs={} response_metadata={} id='56a72377-d70c-4252-b047-035ffcdb34dc'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='84542917-5c0d-4dd4-a034-b480636d2961'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='e37d2f98-3f4e-4879-8ae4-f03404ed93c2'\n",
      "Feedback: The agent outputs provide several hypotheses for repurposing existing drugs for the treatment of acute myeloid leukemia (AML). These hypotheses are detailed and include scientific theories related to specific pathways and mutations in AML, such as FLT3, MAPK/ERK, IDH2, MYC, and BCL-2. However, the outputs do not directly suggest a single drug for repurposing, as asked in the expected result. Instead, multiple potential drugs and targets are presented. Additionally, the outputs are not structured in a cohesive analysis format but rather as separate hypotheses. There is no mention of recent studies or philosophical perspectives, which were part of the expected result.\n",
      "Evaluation Score: 0.6\n",
      "===================================\n",
      "\n",
      "\n",
      "===== Iteration 3 =====\n",
      "Expected Result: Provide an in-depth analysis of the topic:  Suggest an existing drug that could be repurposed for acute myeloid leukemia (AML)treatment The drug should inhibit the proliferation of AML cell lines, including relevant scientific theories, recent studies, and philosophical perspectives.\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='1db90a4f-5cb2-4bc0-a7c4-d62be302a7b2'\n",
      "Unknown output format: content='Hypothesis Generator generated the following hypotheses:\\nTopic: Targeting the FLT3 Pathway in AML\\nHypothesis: Inhibition of the FLT3 receptor tyrosine kinase using the drug midostaurin will lead to a significant decrease in the proliferation of AML cells harboring FLT3-ITD mutations, due to its ability to downregulate the hyperactivated FLT3 signaling pathway, thereby reducing downstream activation of STAT5 and MAPK pathways. This effect will be more pronounced in cell lines with higher expression levels of FLT3-ITD, supporting the potential repurposing of midostaurin as a targeted therapy for FLT3-ITD-positive AML.\\nTopic: Repurposing MEK Inhibitors for AML\\nHypothesis: The MEK1/2 inhibitor trametinib will effectively reduce the survival and proliferation of AML cells exhibiting hyperactivation of the MAPK/ERK pathway, commonly seen in AML patients with RAS mutations. By downregulating the MAPK/ERK signaling cascade, trametinib will induce apoptosis and cell cycle arrest in these cells, providing a rationale for its repurposing as a treatment option for RAS-mutated AML.\\nTopic: Targeting Metabolic Pathways in AML\\nHypothesis: Inhibition of the IDH2 enzyme using the drug enasidenib will result in a significant decrease in the production of the oncometabolite 2-hydroxyglutarate (2-HG) in AML cells with IDH2 mutations. This reduction will lead to the restoration of normal histone and DNA methylation patterns, thereby promoting differentiation and apoptosis of the leukemic cells, supporting the repurposing of enasidenib for IDH2-mutant AML.\\nTopic: Exploiting Epigenetic Modulators in AML\\nHypothesis: The BET bromodomain inhibitor JQ1 will downregulate the expression of MYC and other oncogenes in AML cells with elevated MYC levels, leading to reduced cell proliferation and increased apoptosis. This effect will be more pronounced in AML subtypes characterized by MYC overexpression, suggesting the potential repurposing of JQ1 as a therapeutic strategy for MYC-driven AML.\\nTopic: Targeting Apoptotic Pathways in AML\\nHypothesis: The BCL-2 inhibitor venetoclax, in combination with azacitidine, will synergistically induce apoptosis in AML cells by disrupting BCL-2-mediated survival pathways and enhancing the pro-apoptotic effects of azacitidine. This combination therapy will be particularly effective in AML patients with overexpression of BCL-2, providing a novel approach for the treatment of apoptosis-resistant AML.' additional_kwargs={} response_metadata={} id='d5bc200e-a0d6-46ef-8342-5f79197bae77'\n",
      "Unknown output format: content='Hypothesis Generator generated the following hypotheses:\\nTopic: Targeting the FLT3 Pathway in AML\\nHypothesis: Inhibition of the FLT3 receptor tyrosine kinase using the drug midostaurin will lead to a significant decrease in the proliferation of AML cells harboring FLT3-ITD mutations, due to its ability to downregulate the hyperactivated FLT3 signaling pathway, thereby reducing downstream activation of STAT5 and MAPK pathways. This effect will be more pronounced in cell lines with higher expression levels of FLT3-ITD, supporting the potential repurposing of midostaurin as a targeted therapy for FLT3-ITD-positive AML.\\nTopic: Repurposing MEK Inhibitors for AML\\nHypothesis: The MEK1/2 inhibitor trametinib will effectively reduce the survival and proliferation of AML cells exhibiting hyperactivation of the MAPK/ERK pathway, commonly seen in AML patients with RAS mutations. By downregulating the MAPK/ERK signaling cascade, trametinib will induce apoptosis and cell cycle arrest in these cells, providing a rationale for its repurposing as a treatment option for RAS-mutated AML.\\nTopic: Targeting Metabolic Pathways in AML\\nHypothesis: Inhibition of the IDH2 enzyme using the drug enasidenib will result in a significant decrease in the production of the oncometabolite 2-hydroxyglutarate (2-HG) in AML cells with IDH2 mutations. This reduction will lead to the restoration of normal histone and DNA methylation patterns, thereby promoting differentiation and apoptosis of the leukemic cells, supporting the repurposing of enasidenib for IDH2-mutant AML.\\nTopic: Exploiting Epigenetic Modulators in AML\\nHypothesis: The BET bromodomain inhibitor JQ1 will downregulate the expression of MYC and other oncogenes in AML cells with elevated MYC levels, leading to reduced cell proliferation and increased apoptosis. This effect will be more pronounced in AML subtypes characterized by MYC overexpression, suggesting the potential repurposing of JQ1 as a therapeutic strategy for MYC-driven AML.\\nTopic: Targeting Apoptotic Pathways in AML\\nHypothesis: The BCL-2 inhibitor venetoclax, in combination with azacitidine, will synergistically induce apoptosis in AML cells by disrupting BCL-2-mediated survival pathways and enhancing the pro-apoptotic effects of azacitidine. This combination therapy will be particularly effective in AML patients with overexpression of BCL-2, providing a novel approach for the treatment of apoptosis-resistant AML.' additional_kwargs={} response_metadata={} id='56a72377-d70c-4252-b047-035ffcdb34dc'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='84542917-5c0d-4dd4-a034-b480636d2961'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='e37d2f98-3f4e-4879-8ae4-f03404ed93c2'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='a329014b-922a-4489-b8fd-d0df0859fcf7'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='9c860c3b-c74a-423f-ab12-9d59a889c346'\n",
      "Feedback: The agent outputs provided several hypotheses regarding the repurposing of existing drugs for the treatment of acute myeloid leukemia (AML). These hypotheses focused on targeting specific pathways and mutations associated with AML, such as FLT3, MAPK/ERK, IDH2, MYC, and BCL-2. Each hypothesis included a scientific explanation for why the suggested drug might be effective in inhibiting the proliferation of AML cells. The outputs are relevant to the expected result, as they provide in-depth analysis and scientific theories, although they lack explicit mention of recent studies and philosophical perspectives. Additionally, there were multiple instances of the same output being repeated, and some outputs indicated that no hypotheses were generated, which could suggest issues with consistency or formatting.\n",
      "Evaluation Score: 0.7\n",
      "===================================\n",
      "\n",
      "\n",
      "===== Iteration 4 =====\n",
      "Expected Result: Provide an in-depth analysis of the topic:  Suggest an existing drug that could be repurposed for acute myeloid leukemia (AML)treatment The drug should inhibit the proliferation of AML cell lines, including relevant scientific theories, recent studies, and philosophical perspectives.\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='1db90a4f-5cb2-4bc0-a7c4-d62be302a7b2'\n",
      "Unknown output format: content='Hypothesis Generator generated the following hypotheses:\\nTopic: Targeting the FLT3 Pathway in AML\\nHypothesis: Inhibition of the FLT3 receptor tyrosine kinase using the drug midostaurin will lead to a significant decrease in the proliferation of AML cells harboring FLT3-ITD mutations, due to its ability to downregulate the hyperactivated FLT3 signaling pathway, thereby reducing downstream activation of STAT5 and MAPK pathways. This effect will be more pronounced in cell lines with higher expression levels of FLT3-ITD, supporting the potential repurposing of midostaurin as a targeted therapy for FLT3-ITD-positive AML.\\nTopic: Repurposing MEK Inhibitors for AML\\nHypothesis: The MEK1/2 inhibitor trametinib will effectively reduce the survival and proliferation of AML cells exhibiting hyperactivation of the MAPK/ERK pathway, commonly seen in AML patients with RAS mutations. By downregulating the MAPK/ERK signaling cascade, trametinib will induce apoptosis and cell cycle arrest in these cells, providing a rationale for its repurposing as a treatment option for RAS-mutated AML.\\nTopic: Targeting Metabolic Pathways in AML\\nHypothesis: Inhibition of the IDH2 enzyme using the drug enasidenib will result in a significant decrease in the production of the oncometabolite 2-hydroxyglutarate (2-HG) in AML cells with IDH2 mutations. This reduction will lead to the restoration of normal histone and DNA methylation patterns, thereby promoting differentiation and apoptosis of the leukemic cells, supporting the repurposing of enasidenib for IDH2-mutant AML.\\nTopic: Exploiting Epigenetic Modulators in AML\\nHypothesis: The BET bromodomain inhibitor JQ1 will downregulate the expression of MYC and other oncogenes in AML cells with elevated MYC levels, leading to reduced cell proliferation and increased apoptosis. This effect will be more pronounced in AML subtypes characterized by MYC overexpression, suggesting the potential repurposing of JQ1 as a therapeutic strategy for MYC-driven AML.\\nTopic: Targeting Apoptotic Pathways in AML\\nHypothesis: The BCL-2 inhibitor venetoclax, in combination with azacitidine, will synergistically induce apoptosis in AML cells by disrupting BCL-2-mediated survival pathways and enhancing the pro-apoptotic effects of azacitidine. This combination therapy will be particularly effective in AML patients with overexpression of BCL-2, providing a novel approach for the treatment of apoptosis-resistant AML.' additional_kwargs={} response_metadata={} id='d5bc200e-a0d6-46ef-8342-5f79197bae77'\n",
      "Unknown output format: content='Hypothesis Generator generated the following hypotheses:\\nTopic: Targeting the FLT3 Pathway in AML\\nHypothesis: Inhibition of the FLT3 receptor tyrosine kinase using the drug midostaurin will lead to a significant decrease in the proliferation of AML cells harboring FLT3-ITD mutations, due to its ability to downregulate the hyperactivated FLT3 signaling pathway, thereby reducing downstream activation of STAT5 and MAPK pathways. This effect will be more pronounced in cell lines with higher expression levels of FLT3-ITD, supporting the potential repurposing of midostaurin as a targeted therapy for FLT3-ITD-positive AML.\\nTopic: Repurposing MEK Inhibitors for AML\\nHypothesis: The MEK1/2 inhibitor trametinib will effectively reduce the survival and proliferation of AML cells exhibiting hyperactivation of the MAPK/ERK pathway, commonly seen in AML patients with RAS mutations. By downregulating the MAPK/ERK signaling cascade, trametinib will induce apoptosis and cell cycle arrest in these cells, providing a rationale for its repurposing as a treatment option for RAS-mutated AML.\\nTopic: Targeting Metabolic Pathways in AML\\nHypothesis: Inhibition of the IDH2 enzyme using the drug enasidenib will result in a significant decrease in the production of the oncometabolite 2-hydroxyglutarate (2-HG) in AML cells with IDH2 mutations. This reduction will lead to the restoration of normal histone and DNA methylation patterns, thereby promoting differentiation and apoptosis of the leukemic cells, supporting the repurposing of enasidenib for IDH2-mutant AML.\\nTopic: Exploiting Epigenetic Modulators in AML\\nHypothesis: The BET bromodomain inhibitor JQ1 will downregulate the expression of MYC and other oncogenes in AML cells with elevated MYC levels, leading to reduced cell proliferation and increased apoptosis. This effect will be more pronounced in AML subtypes characterized by MYC overexpression, suggesting the potential repurposing of JQ1 as a therapeutic strategy for MYC-driven AML.\\nTopic: Targeting Apoptotic Pathways in AML\\nHypothesis: The BCL-2 inhibitor venetoclax, in combination with azacitidine, will synergistically induce apoptosis in AML cells by disrupting BCL-2-mediated survival pathways and enhancing the pro-apoptotic effects of azacitidine. This combination therapy will be particularly effective in AML patients with overexpression of BCL-2, providing a novel approach for the treatment of apoptosis-resistant AML.' additional_kwargs={} response_metadata={} id='56a72377-d70c-4252-b047-035ffcdb34dc'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='84542917-5c0d-4dd4-a034-b480636d2961'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='e37d2f98-3f4e-4879-8ae4-f03404ed93c2'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='a329014b-922a-4489-b8fd-d0df0859fcf7'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='9c860c3b-c74a-423f-ab12-9d59a889c346'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='99238dfe-7ed0-47ec-ac9f-f395c3a33b74'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='c9a3be7f-82ca-4a0e-bb29-2a945edc5020'\n",
      "Feedback: The agent outputs contain a series of hypotheses regarding drug repurposing for acute myeloid leukemia (AML). These hypotheses suggest various drugs that could potentially inhibit the proliferation of AML cell lines through different mechanisms, such as targeting the FLT3 pathway, repurposing MEK inhibitors, targeting metabolic and epigenetic pathways, and exploiting apoptotic pathways. The outputs are detailed and provide scientific reasoning for each proposed drug's mechanism of action. However, the expected result was to provide an in-depth analysis, including scientific theories, recent studies, and philosophical perspectives. While the hypotheses do mention potential mechanisms and scientific reasoning, they lack a broader analysis that includes recent studies or philosophical perspectives. Additionally, there are multiple instances of \"Hypothesis Generator did not generate any hypotheses,\" which do not contribute to the analysis. Overall, while the hypotheses are relevant and well-structured, the response does not fully meet the expected depth of analysis.\n",
      "Evaluation Score: 0.6\n",
      "===================================\n",
      "\n",
      "\n",
      "===== Iteration 5 =====\n",
      "Expected Result: Provide an in-depth analysis of the topic:  Suggest an existing drug that could be repurposed for acute myeloid leukemia (AML)treatment The drug should inhibit the proliferation of AML cell lines, including relevant scientific theories, recent studies, and philosophical perspectives.\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='1db90a4f-5cb2-4bc0-a7c4-d62be302a7b2'\n",
      "Unknown output format: content='Hypothesis Generator generated the following hypotheses:\\nTopic: Targeting the FLT3 Pathway in AML\\nHypothesis: Inhibition of the FLT3 receptor tyrosine kinase using the drug midostaurin will lead to a significant decrease in the proliferation of AML cells harboring FLT3-ITD mutations, due to its ability to downregulate the hyperactivated FLT3 signaling pathway, thereby reducing downstream activation of STAT5 and MAPK pathways. This effect will be more pronounced in cell lines with higher expression levels of FLT3-ITD, supporting the potential repurposing of midostaurin as a targeted therapy for FLT3-ITD-positive AML.\\nTopic: Repurposing MEK Inhibitors for AML\\nHypothesis: The MEK1/2 inhibitor trametinib will effectively reduce the survival and proliferation of AML cells exhibiting hyperactivation of the MAPK/ERK pathway, commonly seen in AML patients with RAS mutations. By downregulating the MAPK/ERK signaling cascade, trametinib will induce apoptosis and cell cycle arrest in these cells, providing a rationale for its repurposing as a treatment option for RAS-mutated AML.\\nTopic: Targeting Metabolic Pathways in AML\\nHypothesis: Inhibition of the IDH2 enzyme using the drug enasidenib will result in a significant decrease in the production of the oncometabolite 2-hydroxyglutarate (2-HG) in AML cells with IDH2 mutations. This reduction will lead to the restoration of normal histone and DNA methylation patterns, thereby promoting differentiation and apoptosis of the leukemic cells, supporting the repurposing of enasidenib for IDH2-mutant AML.\\nTopic: Exploiting Epigenetic Modulators in AML\\nHypothesis: The BET bromodomain inhibitor JQ1 will downregulate the expression of MYC and other oncogenes in AML cells with elevated MYC levels, leading to reduced cell proliferation and increased apoptosis. This effect will be more pronounced in AML subtypes characterized by MYC overexpression, suggesting the potential repurposing of JQ1 as a therapeutic strategy for MYC-driven AML.\\nTopic: Targeting Apoptotic Pathways in AML\\nHypothesis: The BCL-2 inhibitor venetoclax, in combination with azacitidine, will synergistically induce apoptosis in AML cells by disrupting BCL-2-mediated survival pathways and enhancing the pro-apoptotic effects of azacitidine. This combination therapy will be particularly effective in AML patients with overexpression of BCL-2, providing a novel approach for the treatment of apoptosis-resistant AML.' additional_kwargs={} response_metadata={} id='d5bc200e-a0d6-46ef-8342-5f79197bae77'\n",
      "Unknown output format: content='Hypothesis Generator generated the following hypotheses:\\nTopic: Targeting the FLT3 Pathway in AML\\nHypothesis: Inhibition of the FLT3 receptor tyrosine kinase using the drug midostaurin will lead to a significant decrease in the proliferation of AML cells harboring FLT3-ITD mutations, due to its ability to downregulate the hyperactivated FLT3 signaling pathway, thereby reducing downstream activation of STAT5 and MAPK pathways. This effect will be more pronounced in cell lines with higher expression levels of FLT3-ITD, supporting the potential repurposing of midostaurin as a targeted therapy for FLT3-ITD-positive AML.\\nTopic: Repurposing MEK Inhibitors for AML\\nHypothesis: The MEK1/2 inhibitor trametinib will effectively reduce the survival and proliferation of AML cells exhibiting hyperactivation of the MAPK/ERK pathway, commonly seen in AML patients with RAS mutations. By downregulating the MAPK/ERK signaling cascade, trametinib will induce apoptosis and cell cycle arrest in these cells, providing a rationale for its repurposing as a treatment option for RAS-mutated AML.\\nTopic: Targeting Metabolic Pathways in AML\\nHypothesis: Inhibition of the IDH2 enzyme using the drug enasidenib will result in a significant decrease in the production of the oncometabolite 2-hydroxyglutarate (2-HG) in AML cells with IDH2 mutations. This reduction will lead to the restoration of normal histone and DNA methylation patterns, thereby promoting differentiation and apoptosis of the leukemic cells, supporting the repurposing of enasidenib for IDH2-mutant AML.\\nTopic: Exploiting Epigenetic Modulators in AML\\nHypothesis: The BET bromodomain inhibitor JQ1 will downregulate the expression of MYC and other oncogenes in AML cells with elevated MYC levels, leading to reduced cell proliferation and increased apoptosis. This effect will be more pronounced in AML subtypes characterized by MYC overexpression, suggesting the potential repurposing of JQ1 as a therapeutic strategy for MYC-driven AML.\\nTopic: Targeting Apoptotic Pathways in AML\\nHypothesis: The BCL-2 inhibitor venetoclax, in combination with azacitidine, will synergistically induce apoptosis in AML cells by disrupting BCL-2-mediated survival pathways and enhancing the pro-apoptotic effects of azacitidine. This combination therapy will be particularly effective in AML patients with overexpression of BCL-2, providing a novel approach for the treatment of apoptosis-resistant AML.' additional_kwargs={} response_metadata={} id='56a72377-d70c-4252-b047-035ffcdb34dc'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='84542917-5c0d-4dd4-a034-b480636d2961'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='e37d2f98-3f4e-4879-8ae4-f03404ed93c2'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='a329014b-922a-4489-b8fd-d0df0859fcf7'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='9c860c3b-c74a-423f-ab12-9d59a889c346'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='99238dfe-7ed0-47ec-ac9f-f395c3a33b74'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='c9a3be7f-82ca-4a0e-bb29-2a945edc5020'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='27c8ade8-f793-41fd-968e-d0b70694b3d8'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='8bda3342-8676-4005-beaf-35c05b966841'\n",
      "Feedback: The expected result asks for an in-depth analysis of a drug that could be repurposed for AML treatment, including scientific theories, studies, and philosophical perspectives. The agent outputs provide several hypotheses for different drugs that could be repurposed to treat AML, which partially addresses the expected result. However, the outputs primarily list hypotheses rather than providing an in-depth analysis or discussing relevant scientific theories and philosophical perspectives. Additionally, some outputs do not contain any hypotheses, which does not meet the requirement for detailed content. Overall, the agent outputs contain relevant information but lack depth and comprehensiveness.\n",
      "Evaluation Score: 0.4\n",
      "===================================\n",
      "\n",
      "Final Agent Outputs:\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='1db90a4f-5cb2-4bc0-a7c4-d62be302a7b2'\n",
      "Unknown output format: content='Hypothesis Generator generated the following hypotheses:\\nTopic: Targeting the FLT3 Pathway in AML\\nHypothesis: Inhibition of the FLT3 receptor tyrosine kinase using the drug midostaurin will lead to a significant decrease in the proliferation of AML cells harboring FLT3-ITD mutations, due to its ability to downregulate the hyperactivated FLT3 signaling pathway, thereby reducing downstream activation of STAT5 and MAPK pathways. This effect will be more pronounced in cell lines with higher expression levels of FLT3-ITD, supporting the potential repurposing of midostaurin as a targeted therapy for FLT3-ITD-positive AML.\\nTopic: Repurposing MEK Inhibitors for AML\\nHypothesis: The MEK1/2 inhibitor trametinib will effectively reduce the survival and proliferation of AML cells exhibiting hyperactivation of the MAPK/ERK pathway, commonly seen in AML patients with RAS mutations. By downregulating the MAPK/ERK signaling cascade, trametinib will induce apoptosis and cell cycle arrest in these cells, providing a rationale for its repurposing as a treatment option for RAS-mutated AML.\\nTopic: Targeting Metabolic Pathways in AML\\nHypothesis: Inhibition of the IDH2 enzyme using the drug enasidenib will result in a significant decrease in the production of the oncometabolite 2-hydroxyglutarate (2-HG) in AML cells with IDH2 mutations. This reduction will lead to the restoration of normal histone and DNA methylation patterns, thereby promoting differentiation and apoptosis of the leukemic cells, supporting the repurposing of enasidenib for IDH2-mutant AML.\\nTopic: Exploiting Epigenetic Modulators in AML\\nHypothesis: The BET bromodomain inhibitor JQ1 will downregulate the expression of MYC and other oncogenes in AML cells with elevated MYC levels, leading to reduced cell proliferation and increased apoptosis. This effect will be more pronounced in AML subtypes characterized by MYC overexpression, suggesting the potential repurposing of JQ1 as a therapeutic strategy for MYC-driven AML.\\nTopic: Targeting Apoptotic Pathways in AML\\nHypothesis: The BCL-2 inhibitor venetoclax, in combination with azacitidine, will synergistically induce apoptosis in AML cells by disrupting BCL-2-mediated survival pathways and enhancing the pro-apoptotic effects of azacitidine. This combination therapy will be particularly effective in AML patients with overexpression of BCL-2, providing a novel approach for the treatment of apoptosis-resistant AML.' additional_kwargs={} response_metadata={} id='d5bc200e-a0d6-46ef-8342-5f79197bae77'\n",
      "Unknown output format: content='Hypothesis Generator generated the following hypotheses:\\nTopic: Targeting the FLT3 Pathway in AML\\nHypothesis: Inhibition of the FLT3 receptor tyrosine kinase using the drug midostaurin will lead to a significant decrease in the proliferation of AML cells harboring FLT3-ITD mutations, due to its ability to downregulate the hyperactivated FLT3 signaling pathway, thereby reducing downstream activation of STAT5 and MAPK pathways. This effect will be more pronounced in cell lines with higher expression levels of FLT3-ITD, supporting the potential repurposing of midostaurin as a targeted therapy for FLT3-ITD-positive AML.\\nTopic: Repurposing MEK Inhibitors for AML\\nHypothesis: The MEK1/2 inhibitor trametinib will effectively reduce the survival and proliferation of AML cells exhibiting hyperactivation of the MAPK/ERK pathway, commonly seen in AML patients with RAS mutations. By downregulating the MAPK/ERK signaling cascade, trametinib will induce apoptosis and cell cycle arrest in these cells, providing a rationale for its repurposing as a treatment option for RAS-mutated AML.\\nTopic: Targeting Metabolic Pathways in AML\\nHypothesis: Inhibition of the IDH2 enzyme using the drug enasidenib will result in a significant decrease in the production of the oncometabolite 2-hydroxyglutarate (2-HG) in AML cells with IDH2 mutations. This reduction will lead to the restoration of normal histone and DNA methylation patterns, thereby promoting differentiation and apoptosis of the leukemic cells, supporting the repurposing of enasidenib for IDH2-mutant AML.\\nTopic: Exploiting Epigenetic Modulators in AML\\nHypothesis: The BET bromodomain inhibitor JQ1 will downregulate the expression of MYC and other oncogenes in AML cells with elevated MYC levels, leading to reduced cell proliferation and increased apoptosis. This effect will be more pronounced in AML subtypes characterized by MYC overexpression, suggesting the potential repurposing of JQ1 as a therapeutic strategy for MYC-driven AML.\\nTopic: Targeting Apoptotic Pathways in AML\\nHypothesis: The BCL-2 inhibitor venetoclax, in combination with azacitidine, will synergistically induce apoptosis in AML cells by disrupting BCL-2-mediated survival pathways and enhancing the pro-apoptotic effects of azacitidine. This combination therapy will be particularly effective in AML patients with overexpression of BCL-2, providing a novel approach for the treatment of apoptosis-resistant AML.' additional_kwargs={} response_metadata={} id='56a72377-d70c-4252-b047-035ffcdb34dc'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='84542917-5c0d-4dd4-a034-b480636d2961'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='e37d2f98-3f4e-4879-8ae4-f03404ed93c2'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='a329014b-922a-4489-b8fd-d0df0859fcf7'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='9c860c3b-c74a-423f-ab12-9d59a889c346'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='99238dfe-7ed0-47ec-ac9f-f395c3a33b74'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='c9a3be7f-82ca-4a0e-bb29-2a945edc5020'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='27c8ade8-f793-41fd-968e-d0b70694b3d8'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='8bda3342-8676-4005-beaf-35c05b966841'\n"
     ]
    }
   ],
   "source": [
    "# Invoke the graph with recursion limit\n",
    "final_state = graph.invoke(initial_state, {\"recursion_limit\": 150})\n",
    "\n",
    "\n",
    "# Print final outputs while handling both AIMessage objects and dictionary outputs\n",
    "print(\"Final Agent Outputs:\")\n",
    "for output in final_state['agent_outputs']:\n",
    "    if hasattr(output, 'role') and hasattr(output, 'content'):\n",
    "        # Handle AIMessage objects\n",
    "        print(f\"{output.role}:\\n{output.content}\\n\")\n",
    "    elif isinstance(output, dict):\n",
    "        # Handle dictionary-style outputs\n",
    "        print(f\"{output.get('agent_name', 'Unknown Agent')}:\\n{output.get('output', '')}\\n\")\n",
    "    else:\n",
    "        # Handle unknown output formats\n",
    "        print(f\"Unknown output format: {output}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "70e5d918-3f3b-4eed-8fb3-fa2463aa8142",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Final Agent Outputs:\n",
      "assistant:\n",
      "Hypothesis Generator did not generate any hypotheses.\n",
      "\n",
      "assistant:\n",
      "Hypothesis Generator generated the following hypotheses:\n",
      "Topic: Targeting the FLT3 Pathway in AML\n",
      "Hypothesis: Inhibition of the FLT3 receptor tyrosine kinase using the drug midostaurin will lead to a significant decrease in the proliferation of AML cells harboring FLT3-ITD mutations, due to its ability to downregulate the hyperactivated FLT3 signaling pathway, thereby reducing downstream activation of STAT5 and MAPK pathways. This effect will be more pronounced in cell lines with higher expression levels of FLT3-ITD, supporting the potential repurposing of midostaurin as a targeted therapy for FLT3-ITD-positive AML.\n",
      "Topic: Repurposing MEK Inhibitors for AML\n",
      "Hypothesis: The MEK1/2 inhibitor trametinib will effectively reduce the survival and proliferation of AML cells exhibiting hyperactivation of the MAPK/ERK pathway, commonly seen in AML patients with RAS mutations. By downregulating the MAPK/ERK signaling cascade, trametinib will induce apoptosis and cell cycle arrest in these cells, providing a rationale for its repurposing as a treatment option for RAS-mutated AML.\n",
      "Topic: Targeting Metabolic Pathways in AML\n",
      "Hypothesis: Inhibition of the IDH2 enzyme using the drug enasidenib will result in a significant decrease in the production of the oncometabolite 2-hydroxyglutarate (2-HG) in AML cells with IDH2 mutations. This reduction will lead to the restoration of normal histone and DNA methylation patterns, thereby promoting differentiation and apoptosis of the leukemic cells, supporting the repurposing of enasidenib for IDH2-mutant AML.\n",
      "Topic: Exploiting Epigenetic Modulators in AML\n",
      "Hypothesis: The BET bromodomain inhibitor JQ1 will downregulate the expression of MYC and other oncogenes in AML cells with elevated MYC levels, leading to reduced cell proliferation and increased apoptosis. This effect will be more pronounced in AML subtypes characterized by MYC overexpression, suggesting the potential repurposing of JQ1 as a therapeutic strategy for MYC-driven AML.\n",
      "Topic: Targeting Apoptotic Pathways in AML\n",
      "Hypothesis: The BCL-2 inhibitor venetoclax, in combination with azacitidine, will synergistically induce apoptosis in AML cells by disrupting BCL-2-mediated survival pathways and enhancing the pro-apoptotic effects of azacitidine. This combination therapy will be particularly effective in AML patients with overexpression of BCL-2, providing a novel approach for the treatment of apoptosis-resistant AML.\n",
      "\n",
      "assistant:\n",
      "Hypothesis Generator generated the following hypotheses:\n",
      "Topic: Targeting the FLT3 Pathway in AML\n",
      "Hypothesis: Inhibition of the FLT3 receptor tyrosine kinase using the drug midostaurin will lead to a significant decrease in the proliferation of AML cells harboring FLT3-ITD mutations, due to its ability to downregulate the hyperactivated FLT3 signaling pathway, thereby reducing downstream activation of STAT5 and MAPK pathways. This effect will be more pronounced in cell lines with higher expression levels of FLT3-ITD, supporting the potential repurposing of midostaurin as a targeted therapy for FLT3-ITD-positive AML.\n",
      "Topic: Repurposing MEK Inhibitors for AML\n",
      "Hypothesis: The MEK1/2 inhibitor trametinib will effectively reduce the survival and proliferation of AML cells exhibiting hyperactivation of the MAPK/ERK pathway, commonly seen in AML patients with RAS mutations. By downregulating the MAPK/ERK signaling cascade, trametinib will induce apoptosis and cell cycle arrest in these cells, providing a rationale for its repurposing as a treatment option for RAS-mutated AML.\n",
      "Topic: Targeting Metabolic Pathways in AML\n",
      "Hypothesis: Inhibition of the IDH2 enzyme using the drug enasidenib will result in a significant decrease in the production of the oncometabolite 2-hydroxyglutarate (2-HG) in AML cells with IDH2 mutations. This reduction will lead to the restoration of normal histone and DNA methylation patterns, thereby promoting differentiation and apoptosis of the leukemic cells, supporting the repurposing of enasidenib for IDH2-mutant AML.\n",
      "Topic: Exploiting Epigenetic Modulators in AML\n",
      "Hypothesis: The BET bromodomain inhibitor JQ1 will downregulate the expression of MYC and other oncogenes in AML cells with elevated MYC levels, leading to reduced cell proliferation and increased apoptosis. This effect will be more pronounced in AML subtypes characterized by MYC overexpression, suggesting the potential repurposing of JQ1 as a therapeutic strategy for MYC-driven AML.\n",
      "Topic: Targeting Apoptotic Pathways in AML\n",
      "Hypothesis: The BCL-2 inhibitor venetoclax, in combination with azacitidine, will synergistically induce apoptosis in AML cells by disrupting BCL-2-mediated survival pathways and enhancing the pro-apoptotic effects of azacitidine. This combination therapy will be particularly effective in AML patients with overexpression of BCL-2, providing a novel approach for the treatment of apoptosis-resistant AML.\n",
      "\n",
      "assistant:\n",
      "Hypothesis Generator did not generate any hypotheses.\n",
      "\n",
      "assistant:\n",
      "Hypothesis Generator did not generate any hypotheses.\n",
      "\n",
      "assistant:\n",
      "Hypothesis Generator did not generate any hypotheses.\n",
      "\n",
      "assistant:\n",
      "Hypothesis Generator did not generate any hypotheses.\n",
      "\n",
      "assistant:\n",
      "Hypothesis Generator did not generate any hypotheses.\n",
      "\n",
      "assistant:\n",
      "Hypothesis Generator did not generate any hypotheses.\n",
      "\n",
      "assistant:\n",
      "Hypothesis Generator did not generate any hypotheses.\n",
      "\n",
      "assistant:\n",
      "Hypothesis Generator did not generate any hypotheses.\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# Normalize output to standard dictionary format with 'role' and 'content' keys\n",
    "def normalize_output(output):\n",
    "    if hasattr(output, 'role') and hasattr(output, 'content'):\n",
    "        return {\"role\": output.role, \"content\": output.content}\n",
    "    elif isinstance(output, dict):\n",
    "        return {\"role\": output.get('role', 'unknown'), \"content\": output.get('content', '')}\n",
    "    elif hasattr(output, 'content'):  # Custom object handling\n",
    "        return {\"role\": \"assistant\", \"content\": output.content}\n",
    "    else:\n",
    "        return {\"role\": \"unknown\", \"content\": str(output)}\n",
    "\n",
    "\n",
    "# Print final outputs after normalizing the output format\n",
    "print(\"Final Agent Outputs:\")\n",
    "for output in final_state['agent_outputs']:\n",
    "    normalized = normalize_output(output)\n",
    "    print(f\"{normalized['role']}:\\n{normalized['content']}\\n\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "0fa743ce-f522-4ca2-83f5-54bde2b39a3c",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Function to invoke the graph and print results at each iteration\n",
    "def run_graph(graph, initial_state, max_iterations=15):\n",
    "    # Start invoking the graph\n",
    "    state = initial_state\n",
    "\n",
    "    for iteration in range(max_iterations):\n",
    "        print(f\"\\nðŸ”„===== Iteration {iteration + 1} =====\\n\")\n",
    "        \n",
    "        # Run the graph for the current state\n",
    "        state = graph.invoke(state, {\"recursion_limit\": 15})\n",
    "\n",
    "        # Print Expected Result\n",
    "        print(f\"Expected Result:\\n{state.get('expected_result', 'No expected result provided.')}\\n\")\n",
    "\n",
    "        # Print Generated Hypotheses\n",
    "        hypotheses = state.get('hypotheses', [])\n",
    "        if hypotheses:\n",
    "            print(\"Generated Hypotheses:\")\n",
    "            for hypothesis in hypotheses:\n",
    "                print(f\"- Topic: {hypothesis['Topic']}\")\n",
    "                print(f\"  Hypothesis: {hypothesis['Hypothesis']}\\n\")\n",
    "        else:\n",
    "            print(\"No hypotheses generated in this iteration.\\n\")\n",
    "\n",
    "        # Print Agent Outputs\n",
    "        agent_outputs = state.get('agent_outputs', [])\n",
    "        if agent_outputs:\n",
    "            print(\"Agent Outputs:\")\n",
    "            for output in agent_outputs:\n",
    "                print(f\"{output['agent_name']}:\\n{output['output']}\\n\")\n",
    "        else:\n",
    "            print(\"No agent outputs yet.\\n\")\n",
    "\n",
    "        # Print Feedback and Evaluation Score\n",
    "        print(f\"Feedback: {state.get('feedback', 'No feedback')}\")\n",
    "        print(f\"Evaluation Score: {state.get('evaluation', 0.0)}\\n\")\n",
    "        \n",
    "        # Check if loop should continue\n",
    "        if not state.get('continue_loop', False):\n",
    "            print(\"\\nâœ… Workflow completed. No further iterations required.\\n\")\n",
    "            break\n",
    "\n",
    "    # Print final results after loop ends\n",
    "    print(\"\\nðŸŽ¯ ===== Final Results After All Iterations =====\\n\")\n",
    "    print(f\"Total Iterations Run: {state['iteration']}\")\n",
    "    print(f\"Final Feedback: {state.get('feedback', 'No feedback')}\")\n",
    "    print(f\"Final Evaluation Score: {state.get('evaluation', 0.0)}\")\n",
    "\n",
    "    final_hypotheses = state.get('hypotheses', [])\n",
    "    if final_hypotheses:\n",
    "        print(\"\\nFinal Hypotheses:\")\n",
    "        for hypothesis in final_hypotheses:\n",
    "            print(f\"- Topic: {hypothesis['Topic']}\")\n",
    "            print(f\"  Hypothesis: {hypothesis['Hypothesis']}\\n\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "7606c2da-389b-4883-8657-400a537c679e",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "# Helper function to normalize outputs\n",
    "def normalize_output(output):\n",
    "    if hasattr(output, 'role') and hasattr(output, 'content'):\n",
    "        return {\"role\": output.role, \"content\": output.content}\n",
    "    elif isinstance(output, dict):\n",
    "        return {\"role\": output.get('role', 'unknown'), \"content\": output.get('content', '')}\n",
    "    elif hasattr(output, 'content'):  # Handle custom output objects\n",
    "        return {\"role\": \"assistant\", \"content\": output.content}\n",
    "    else:\n",
    "        return {\"role\": \"unknown\", \"content\": str(output)}\n",
    "\n",
    "# Save results to a text file\n",
    "def save_results_to_text(final_state, filename=\"final_results.txt\"):\n",
    "    with open(filename, \"w\") as file:\n",
    "        file.write(\"ðŸŽ¯ ===== Final Results After All Iterations =====\\n\")\n",
    "        file.write(f\"Total Iterations Run: {final_state['iteration']}\\n\")\n",
    "        file.write(f\"Final Feedback: {final_state.get('feedback', 'No feedback')}\\n\")\n",
    "        file.write(f\"Final Evaluation Score: {final_state.get('evaluation', 0.0)}\\n\\n\")\n",
    "\n",
    "        final_hypotheses = final_state.get('hypotheses', [])\n",
    "        if final_hypotheses:\n",
    "            file.write(\"Final Hypotheses:\\n\")\n",
    "            for hypothesis in final_hypotheses:\n",
    "                file.write(f\"- Topic: {hypothesis['Topic']}\\n\")\n",
    "                file.write(f\"  Hypothesis: {hypothesis['Hypothesis']}\\n\\n\")\n",
    "\n",
    "# Save results to a JSON file\n",
    "def save_results_to_json(final_state, filename=\"final_results.json\"):\n",
    "    with open(filename, \"w\") as json_file:\n",
    "        json.dump(final_state, json_file, indent=4)\n",
    "\n",
    "# Updated run_graph function with saving feature\n",
    "def run_graph(graph, initial_state, max_iterations=15):\n",
    "    state = initial_state\n",
    "\n",
    "    for iteration in range(max_iterations):\n",
    "        print(f\"\\nðŸ”„===== Iteration {iteration + 1} =====\\n\")\n",
    "        \n",
    "        state = graph.invoke(state, {\"recursion_limit\": 15})\n",
    "\n",
    "        # Print Expected Result\n",
    "        print(f\"Expected Result:\\n{state.get('expected_result', 'No expected result provided.')}\\n\")\n",
    "\n",
    "        # Print Generated Hypotheses\n",
    "        hypotheses = state.get('hypotheses', [])\n",
    "        if hypotheses:\n",
    "            print(\"Generated Hypotheses:\")\n",
    "            for hypothesis in hypotheses:\n",
    "                print(f\"- Topic: {hypothesis['Topic']}\")\n",
    "                print(f\"  Hypothesis: {hypothesis['Hypothesis']}\\n\")\n",
    "        else:\n",
    "            print(\"No hypotheses generated in this iteration.\\n\")\n",
    "\n",
    "        # Print Agent Outputs using normalized output format\n",
    "        agent_outputs = state.get('agent_outputs', [])\n",
    "        if agent_outputs:\n",
    "            print(\"Agent Outputs:\")\n",
    "            for output in agent_outputs:\n",
    "                normalized = normalize_output(output)\n",
    "                print(f\"{normalized['role']}:\\n{normalized['content']}\\n\")\n",
    "        else:\n",
    "            print(\"No agent outputs yet.\\n\")\n",
    "\n",
    "        # Print Feedback and Evaluation Score\n",
    "        print(f\"Feedback: {state.get('feedback', 'No feedback')}\")\n",
    "        print(f\"Evaluation Score: {state.get('evaluation', 0.0)}\\n\")\n",
    "        \n",
    "        if not state.get('continue_loop', False):\n",
    "            print(\"\\nâœ… Workflow completed. No further iterations required.\\n\")\n",
    "            break\n",
    "\n",
    "    # Save results after completion\n",
    "    save_results_to_text(state, \"final_results.txt\")\n",
    "    save_results_to_json(state, \"final_results.json\")\n",
    "\n",
    "    # Print final results\n",
    "    print(\"\\nðŸŽ¯ ===== Final Results After All Iterations =====\\n\")\n",
    "    print(f\"Total Iterations Run: {state['iteration']}\")\n",
    "    print(f\"Final Feedback: {state.get('feedback', 'No feedback')}\")\n",
    "    print(f\"Final Evaluation Score: {state.get('evaluation', 0.0)}\")\n",
    "\n",
    "    final_hypotheses = state.get('hypotheses', [])\n",
    "    if final_hypotheses:\n",
    "        print(\"\\nFinal Hypotheses:\")\n",
    "        for hypothesis in final_hypotheses:\n",
    "            print(f\"- Topic: {hypothesis['Topic']}\")\n",
    "            print(f\"  Hypothesis: {hypothesis['Hypothesis']}\\n\")\n",
    "\n",
    "    print(\"\\nðŸ“ Results have been saved to 'final_results.txt' and 'final_results.json'.\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "e3a0aab8-bf8e-4e45-81c3-f309377ae2bc",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "ðŸ”„===== Iteration 1 =====\n",
      "\n",
      "\n",
      "===== Iteration 1 =====\n",
      "Expected Result: Provide an in-depth analysis of the topic:  Suggest an existing drug that could be repurposed for acute myeloid leukemia (AML)treatment The drug should inhibit the proliferation of AML cell lines, including relevant scientific theories, recent studies, and philosophical perspectives.\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='fc748f05-2c3a-434f-86f7-cf555c4df35a'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='6509301b-2473-448e-8e73-77c522d3d853'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='2d708640-ad91-48ca-b7ce-eaec9e616eb5'\n",
      "Feedback: The agent outputs do not align with the expected result. The task was to provide an in-depth analysis of a potential drug that could be repurposed for treating acute myeloid leukemia (AML). This includes discussing the drug's mechanism of action, relevant scientific theories, recent studies, and philosophical perspectives on drug repurposing. However, the agent outputs are placeholders indicating that no hypotheses were generated, and they do not contain any relevant information about AML or drug repurposing. Therefore, the outputs fail to meet the requirements of the task.\n",
      "Evaluation Score: 0.0\n",
      "===================================\n",
      "\n",
      "\n",
      "===== Iteration 2 =====\n",
      "Expected Result: Provide an in-depth analysis of the topic:  Suggest an existing drug that could be repurposed for acute myeloid leukemia (AML)treatment The drug should inhibit the proliferation of AML cell lines, including relevant scientific theories, recent studies, and philosophical perspectives.\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='fc748f05-2c3a-434f-86f7-cf555c4df35a'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='6509301b-2473-448e-8e73-77c522d3d853'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='2d708640-ad91-48ca-b7ce-eaec9e616eb5'\n",
      "Unknown output format: content='Hypothesis Generator generated the following hypotheses:\\nTopic: Repurposing Metformin for Acute Myeloid Leukemia (AML)\\nHypothesis: Metformin, a drug traditionally used for the treatment of Type 2 diabetes, can be repurposed for the treatment of acute myeloid leukemia by targeting the upregulated mTOR signaling pathway. Preclinical studies have indicated that AML cells often exhibit dysregulation in the mTOR pathway, leading to increased cell proliferation and survival. Metformin is known to inhibit this pathway by activating AMP-activated protein kinase (AMPK), which in turn downregulates mTOR activity. This downregulation could reduce the proliferation of AML cells and induce apoptosis, offering a novel therapeutic approach for AML treatment.\\nTopic: Repurposing Itraconazole for Acute Myeloid Leukemia (AML)\\nHypothesis: Itraconazole, an antifungal agent, can be repurposed to treat acute myeloid leukemia by inhibiting the Hedgehog signaling pathway, which is often upregulated in AML. The Hedgehog pathway plays a critical role in the maintenance of cancer stem cells and the proliferation of leukemia cells. Itraconazole has been shown to disrupt this pathway, leading to reduced viability of cancer cells. Therefore, its repurposing for AML could provide an effective strategy to target leukemia stem cells and reduce disease progression.\\nTopic: Repurposing Disulfiram for Acute Myeloid Leukemia (AML)\\nHypothesis: Disulfiram, a drug used for alcohol aversion therapy, can be repurposed for the treatment of acute myeloid leukemia by inhibiting the proteasome pathway, which is frequently upregulated in AML. Disulfiram has been demonstrated to inhibit the proteasome activity via copper-dependent mechanisms, leading to the accumulation of ubiquitinated proteins and induction of apoptosis in cancer cells. Therefore, its application in AML could selectively target leukemia cells, providing a new therapeutic avenue.\\nTopic: Repurposing Auranofin for Acute Myeloid Leukemia (AML)\\nHypothesis: Auranofin, a gold-containing compound used for rheumatoid arthritis, can be repurposed for the treatment of acute myeloid leukemia by targeting the thioredoxin reductase enzyme, which is often upregulated in AML. Inhibition of thioredoxin reductase by Auranofin leads to increased oxidative stress and apoptosis in leukemia cells. Given the high metabolic activity and oxidative stress levels in AML, this approach could selectively induce cell death in leukemia cells while sparing normal cells.' additional_kwargs={} response_metadata={} id='a799d3bb-7648-484b-8a62-1c83b268232f'\n",
      "Unknown output format: content='Hypothesis Generator generated the following hypotheses:\\nTopic: Repurposing Metformin for Acute Myeloid Leukemia (AML)\\nHypothesis: Metformin, a drug traditionally used for the treatment of Type 2 diabetes, can be repurposed for the treatment of acute myeloid leukemia by targeting the upregulated mTOR signaling pathway. Preclinical studies have indicated that AML cells often exhibit dysregulation in the mTOR pathway, leading to increased cell proliferation and survival. Metformin is known to inhibit this pathway by activating AMP-activated protein kinase (AMPK), which in turn downregulates mTOR activity. This downregulation could reduce the proliferation of AML cells and induce apoptosis, offering a novel therapeutic approach for AML treatment.\\nTopic: Repurposing Itraconazole for Acute Myeloid Leukemia (AML)\\nHypothesis: Itraconazole, an antifungal agent, can be repurposed to treat acute myeloid leukemia by inhibiting the Hedgehog signaling pathway, which is often upregulated in AML. The Hedgehog pathway plays a critical role in the maintenance of cancer stem cells and the proliferation of leukemia cells. Itraconazole has been shown to disrupt this pathway, leading to reduced viability of cancer cells. Therefore, its repurposing for AML could provide an effective strategy to target leukemia stem cells and reduce disease progression.\\nTopic: Repurposing Disulfiram for Acute Myeloid Leukemia (AML)\\nHypothesis: Disulfiram, a drug used for alcohol aversion therapy, can be repurposed for the treatment of acute myeloid leukemia by inhibiting the proteasome pathway, which is frequently upregulated in AML. Disulfiram has been demonstrated to inhibit the proteasome activity via copper-dependent mechanisms, leading to the accumulation of ubiquitinated proteins and induction of apoptosis in cancer cells. Therefore, its application in AML could selectively target leukemia cells, providing a new therapeutic avenue.\\nTopic: Repurposing Auranofin for Acute Myeloid Leukemia (AML)\\nHypothesis: Auranofin, a gold-containing compound used for rheumatoid arthritis, can be repurposed for the treatment of acute myeloid leukemia by targeting the thioredoxin reductase enzyme, which is often upregulated in AML. Inhibition of thioredoxin reductase by Auranofin leads to increased oxidative stress and apoptosis in leukemia cells. Given the high metabolic activity and oxidative stress levels in AML, this approach could selectively induce cell death in leukemia cells while sparing normal cells.' additional_kwargs={} response_metadata={} id='f4e5edf9-fded-49f1-b585-dd51d8cde48e'\n",
      "Feedback: The agent provided a set of hypotheses for repurposing existing drugs for the treatment of acute myeloid leukemia (AML). The suggestions included Metformin, Itraconazole, Disulfiram, and Auranofin, each with a brief explanation of their potential mechanisms of action in inhibiting AML cell proliferation. However, the response lacks an in-depth analysis or discussion of recent scientific studies and philosophical perspectives, which were part of the expected result. Additionally, the agent's response format included repeated outputs and some irrelevant information, which could have been consolidated into a single cohesive analysis.\n",
      "Evaluation Score: 0.6\n",
      "===================================\n",
      "\n",
      "\n",
      "===== Iteration 3 =====\n",
      "Expected Result: Provide an in-depth analysis of the topic:  Suggest an existing drug that could be repurposed for acute myeloid leukemia (AML)treatment The drug should inhibit the proliferation of AML cell lines, including relevant scientific theories, recent studies, and philosophical perspectives.\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='fc748f05-2c3a-434f-86f7-cf555c4df35a'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='6509301b-2473-448e-8e73-77c522d3d853'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='2d708640-ad91-48ca-b7ce-eaec9e616eb5'\n",
      "Unknown output format: content='Hypothesis Generator generated the following hypotheses:\\nTopic: Repurposing Metformin for Acute Myeloid Leukemia (AML)\\nHypothesis: Metformin, a drug traditionally used for the treatment of Type 2 diabetes, can be repurposed for the treatment of acute myeloid leukemia by targeting the upregulated mTOR signaling pathway. Preclinical studies have indicated that AML cells often exhibit dysregulation in the mTOR pathway, leading to increased cell proliferation and survival. Metformin is known to inhibit this pathway by activating AMP-activated protein kinase (AMPK), which in turn downregulates mTOR activity. This downregulation could reduce the proliferation of AML cells and induce apoptosis, offering a novel therapeutic approach for AML treatment.\\nTopic: Repurposing Itraconazole for Acute Myeloid Leukemia (AML)\\nHypothesis: Itraconazole, an antifungal agent, can be repurposed to treat acute myeloid leukemia by inhibiting the Hedgehog signaling pathway, which is often upregulated in AML. The Hedgehog pathway plays a critical role in the maintenance of cancer stem cells and the proliferation of leukemia cells. Itraconazole has been shown to disrupt this pathway, leading to reduced viability of cancer cells. Therefore, its repurposing for AML could provide an effective strategy to target leukemia stem cells and reduce disease progression.\\nTopic: Repurposing Disulfiram for Acute Myeloid Leukemia (AML)\\nHypothesis: Disulfiram, a drug used for alcohol aversion therapy, can be repurposed for the treatment of acute myeloid leukemia by inhibiting the proteasome pathway, which is frequently upregulated in AML. Disulfiram has been demonstrated to inhibit the proteasome activity via copper-dependent mechanisms, leading to the accumulation of ubiquitinated proteins and induction of apoptosis in cancer cells. Therefore, its application in AML could selectively target leukemia cells, providing a new therapeutic avenue.\\nTopic: Repurposing Auranofin for Acute Myeloid Leukemia (AML)\\nHypothesis: Auranofin, a gold-containing compound used for rheumatoid arthritis, can be repurposed for the treatment of acute myeloid leukemia by targeting the thioredoxin reductase enzyme, which is often upregulated in AML. Inhibition of thioredoxin reductase by Auranofin leads to increased oxidative stress and apoptosis in leukemia cells. Given the high metabolic activity and oxidative stress levels in AML, this approach could selectively induce cell death in leukemia cells while sparing normal cells.' additional_kwargs={} response_metadata={} id='a799d3bb-7648-484b-8a62-1c83b268232f'\n",
      "Unknown output format: content='Hypothesis Generator generated the following hypotheses:\\nTopic: Repurposing Metformin for Acute Myeloid Leukemia (AML)\\nHypothesis: Metformin, a drug traditionally used for the treatment of Type 2 diabetes, can be repurposed for the treatment of acute myeloid leukemia by targeting the upregulated mTOR signaling pathway. Preclinical studies have indicated that AML cells often exhibit dysregulation in the mTOR pathway, leading to increased cell proliferation and survival. Metformin is known to inhibit this pathway by activating AMP-activated protein kinase (AMPK), which in turn downregulates mTOR activity. This downregulation could reduce the proliferation of AML cells and induce apoptosis, offering a novel therapeutic approach for AML treatment.\\nTopic: Repurposing Itraconazole for Acute Myeloid Leukemia (AML)\\nHypothesis: Itraconazole, an antifungal agent, can be repurposed to treat acute myeloid leukemia by inhibiting the Hedgehog signaling pathway, which is often upregulated in AML. The Hedgehog pathway plays a critical role in the maintenance of cancer stem cells and the proliferation of leukemia cells. Itraconazole has been shown to disrupt this pathway, leading to reduced viability of cancer cells. Therefore, its repurposing for AML could provide an effective strategy to target leukemia stem cells and reduce disease progression.\\nTopic: Repurposing Disulfiram for Acute Myeloid Leukemia (AML)\\nHypothesis: Disulfiram, a drug used for alcohol aversion therapy, can be repurposed for the treatment of acute myeloid leukemia by inhibiting the proteasome pathway, which is frequently upregulated in AML. Disulfiram has been demonstrated to inhibit the proteasome activity via copper-dependent mechanisms, leading to the accumulation of ubiquitinated proteins and induction of apoptosis in cancer cells. Therefore, its application in AML could selectively target leukemia cells, providing a new therapeutic avenue.\\nTopic: Repurposing Auranofin for Acute Myeloid Leukemia (AML)\\nHypothesis: Auranofin, a gold-containing compound used for rheumatoid arthritis, can be repurposed for the treatment of acute myeloid leukemia by targeting the thioredoxin reductase enzyme, which is often upregulated in AML. Inhibition of thioredoxin reductase by Auranofin leads to increased oxidative stress and apoptosis in leukemia cells. Given the high metabolic activity and oxidative stress levels in AML, this approach could selectively induce cell death in leukemia cells while sparing normal cells.' additional_kwargs={} response_metadata={} id='f4e5edf9-fded-49f1-b585-dd51d8cde48e'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='1c8e7a1a-1d2b-4830-b17e-c8190e34ee8d'\n",
      "Unknown output format: content='Hypothesis Generator did not generate any hypotheses.' additional_kwargs={} response_metadata={} id='77109473-573f-4f95-a891-10c9ca1437e3'\n",
      "Feedback: The expected result requests an in-depth analysis of repurposing an existing drug for acute myeloid leukemia (AML) treatment, including scientific theories, recent studies, and philosophical perspectives. The agent outputs provide hypotheses about repurposing several drugs (Metformin, Itraconazole, Disulfiram, and Auranofin) for AML treatment, including potential mechanisms of action and pathways involved. However, the outputs lack detailed analysis, recent study references, or philosophical perspectives which are required for a comprehensive response. The repetition of hypotheses in the outputs also indicates a lack of variety in the content generated.\n",
      "Evaluation Score: 0.4\n",
      "===================================\n",
      "\n"
     ]
    },
    {
     "ename": "GraphRecursionError",
     "evalue": "Recursion limit of 15 reached without hitting a stop condition. You can increase the limit by setting the `recursion_limit` config key.\nFor troubleshooting, visit: https://python.langchain.com/docs/troubleshooting/errors/GRAPH_RECURSION_LIMIT",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mGraphRecursionError\u001b[0m                       Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[13], line 2\u001b[0m\n\u001b[0;32m      1\u001b[0m \u001b[38;5;66;03m# Run the graph and print out each iteration\u001b[39;00m\n\u001b[1;32m----> 2\u001b[0m \u001b[43mrun_graph\u001b[49m\u001b[43m(\u001b[49m\u001b[43mgraph\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43minitial_state\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_iterations\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;241;43m15\u001b[39;49m\u001b[43m)\u001b[49m\n",
      "Cell \u001b[1;32mIn[12], line 41\u001b[0m, in \u001b[0;36mrun_graph\u001b[1;34m(graph, initial_state, max_iterations)\u001b[0m\n\u001b[0;32m     38\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m iteration \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mrange\u001b[39m(max_iterations):\n\u001b[0;32m     39\u001b[0m     \u001b[38;5;28mprint\u001b[39m(\u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;124mðŸ”„===== Iteration \u001b[39m\u001b[38;5;132;01m{\u001b[39;00miteration\u001b[38;5;250m \u001b[39m\u001b[38;5;241m+\u001b[39m\u001b[38;5;250m \u001b[39m\u001b[38;5;241m1\u001b[39m\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m =====\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m---> 41\u001b[0m     state \u001b[38;5;241m=\u001b[39m \u001b[43mgraph\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43minvoke\u001b[49m\u001b[43m(\u001b[49m\u001b[43mstate\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrecursion_limit\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m15\u001b[39;49m\u001b[43m}\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m     43\u001b[0m     \u001b[38;5;66;03m# Print Expected Result\u001b[39;00m\n\u001b[0;32m     44\u001b[0m     \u001b[38;5;28mprint\u001b[39m(\u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mExpected Result:\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;132;01m{\u001b[39;00mstate\u001b[38;5;241m.\u001b[39mget(\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mexpected_result\u001b[39m\u001b[38;5;124m'\u001b[39m,\u001b[38;5;250m \u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mNo expected result provided.\u001b[39m\u001b[38;5;124m'\u001b[39m)\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;124m\"\u001b[39m)\n",
      "File \u001b[1;32m~\\venv1\\Lib\\site-packages\\langgraph\\pregel\\__init__.py:1936\u001b[0m, in \u001b[0;36mPregel.invoke\u001b[1;34m(self, input, config, stream_mode, output_keys, interrupt_before, interrupt_after, debug, **kwargs)\u001b[0m\n\u001b[0;32m   1934\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[0;32m   1935\u001b[0m     chunks \u001b[38;5;241m=\u001b[39m []\n\u001b[1;32m-> 1936\u001b[0m \u001b[43m\u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mchunk\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m(\u001b[49m\n\u001b[0;32m   1937\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;28;43minput\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1938\u001b[0m \u001b[43m    \u001b[49m\u001b[43mconfig\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1939\u001b[0m \u001b[43m    \u001b[49m\u001b[43mstream_mode\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream_mode\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1940\u001b[0m \u001b[43m    \u001b[49m\u001b[43moutput_keys\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43moutput_keys\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1941\u001b[0m \u001b[43m    \u001b[49m\u001b[43minterrupt_before\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43minterrupt_before\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1942\u001b[0m \u001b[43m    \u001b[49m\u001b[43minterrupt_after\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43minterrupt_after\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1943\u001b[0m \u001b[43m    \u001b[49m\u001b[43mdebug\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mdebug\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1944\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[0;32m   1945\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\u001b[43m:\u001b[49m\n\u001b[0;32m   1946\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;28;43;01mif\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mstream_mode\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m==\u001b[39;49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mvalues\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\n\u001b[0;32m   1947\u001b[0m \u001b[43m        \u001b[49m\u001b[43mlatest\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m \u001b[49m\u001b[43mchunk\u001b[49m\n",
      "File \u001b[1;32m~\\venv1\\Lib\\site-packages\\langgraph\\pregel\\__init__.py:1676\u001b[0m, in \u001b[0;36mPregel.stream\u001b[1;34m(self, input, config, stream_mode, output_keys, interrupt_before, interrupt_after, debug, subgraphs)\u001b[0m\n\u001b[0;32m   1667\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m loop\u001b[38;5;241m.\u001b[39mstatus \u001b[38;5;241m==\u001b[39m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mout_of_steps\u001b[39m\u001b[38;5;124m\"\u001b[39m:\n\u001b[0;32m   1668\u001b[0m     msg \u001b[38;5;241m=\u001b[39m create_error_message(\n\u001b[0;32m   1669\u001b[0m         message\u001b[38;5;241m=\u001b[39m(\n\u001b[0;32m   1670\u001b[0m             \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mRecursion limit of \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mconfig[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mrecursion_limit\u001b[39m\u001b[38;5;124m'\u001b[39m]\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m reached \u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m   1674\u001b[0m         error_code\u001b[38;5;241m=\u001b[39mErrorCode\u001b[38;5;241m.\u001b[39mGRAPH_RECURSION_LIMIT,\n\u001b[0;32m   1675\u001b[0m     )\n\u001b[1;32m-> 1676\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m GraphRecursionError(msg)\n\u001b[0;32m   1677\u001b[0m \u001b[38;5;66;03m# set final channel values as run output\u001b[39;00m\n\u001b[0;32m   1678\u001b[0m run_manager\u001b[38;5;241m.\u001b[39mon_chain_end(loop\u001b[38;5;241m.\u001b[39moutput)\n",
      "\u001b[1;31mGraphRecursionError\u001b[0m: Recursion limit of 15 reached without hitting a stop condition. You can increase the limit by setting the `recursion_limit` config key.\nFor troubleshooting, visit: https://python.langchain.com/docs/troubleshooting/errors/GRAPH_RECURSION_LIMIT"
     ]
    }
   ],
   "source": [
    "# Run the graph and print out each iteration\n",
    "run_graph(graph, initial_state, max_iterations=15)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "f707ffba-63a1-4ea4-a752-cde3497c4937",
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'final_hypotheses' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[28], line 1\u001b[0m\n\u001b[1;32m----> 1\u001b[0m \u001b[43mfinal_hypotheses\u001b[49m\n",
      "\u001b[1;31mNameError\u001b[0m: name 'final_hypotheses' is not defined"
     ]
    }
   ],
   "source": [
    "final_hypotheses"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "038880ad-7b7a-450e-b117-a3f94ecb8b8a",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "venv1",
   "language": "python",
   "name": "venv1"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
